TY 2010 Form 990

(A) Name and Title	(B) Average hours per week (describe hours for related organizations in Schedule O)	(C) Position (check all that apply)
(1) Douglas Walker Trustee, Chair	5	X
(2) Steve Davis Trustee, Vice Chair	5	X
(3) Richard Anderson Trustee	2	X
(4) Hollis Dillon Trustee	2	X
(5) Karl Ege Treasurer	6	X
(6) Karen Glover Trustee	3	X
(7) Ronald Howell Trustee	2	X
(8) Peter Horvitz Trustee	1	X
(9) Don Listwin Trustee	1	X
(10) Richard McCune Trustee	1	X
(11) Karen Moyer Trustee	1	X
(12) Sally Narodick Trustee, Immediate Past Chair	2	X
(13) Robert Nelson Trustee	1	X
(14) Peter Neupert Trustee	1	X
(15) Charles Nolan Trustee	1	X
(16) James Sinegal Trustee	2	X
(17) Stephen Sundborg Trustee	1	X

(A) Name and Title	(B) Average hours per week (describe hours for related organizations in Schedule O)	(C) Position (check all that apply)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
(18) Vijay Vashee Trustee	2	X					0	0
(19) Douglas Williams Trustee, Secretary	2	X					0	0
(20) Stephen Graham Trustee	2	X					0	0
(21) Lawrence Corey President & Director (Effective 1/1/2011)	9		X				125,802	0
(22) Leland H Hartwell President & Director	40		X				592,890	41,293
(23) Frederick R Appelbaum Sr VP & Dir, Clin Res Div	40		X				588,354	43,686
(24) Janell E Baldwin VP Shared Resources	40		X				202,337	32,522
(25) Anthony Bozzuti VP & Chief Information Officer	40		X				255,756	16,074
(26) Jonathan Cooper Sr VP & Dir, Basic Sci	40		X				262,763	38,493
(27) Linda L Gainer VP External Affairs & Comm	40		X				246,720	43,292
(28) Mark T Groudine Sr VP & Deputy Dir, FHCRC	40		X				468,180	61,056
(29) Randall C Main VP & Chief Financial Officer	40		X				368,324	44,556
(30) Margaret Juliana McElrath Sr VP & Co-Dir, VIDD	40		X				232,458	59,191
(31) Ulrich W Mueller VP Industry Rel & Tech Transfer	40		X				252,869	47,322
(32) Howard Albert Nachtrieb VP Human Resources	40		X				242,965	47,250
(33) Ross L Prentice Sr VP & Dir, PHS	40		X				399,255	44,538
(34) Scott N Rusch VP Operations & Facilities	40		X				201,776	38,218
(35) Douglas J Shaeffer VP General Counsel	40		X				319,538	44,807
(36) Myra H Tanita Exec VP & COO	40		X				473,212	45,780
(37) Barbara Trask Sr VP & Dir, Human Biology	40		X				284,882	56,778
(38) Steven G Self Co-Dir, VIDD	40			X			281,222	67,642
(39) Irwin D Bernstein Full Member	40				X		295,080	59,165
(40) Martin A Cheever Full Member	40				X		288,162	56,695
(41) Samir M Hanash Full Member	40				X		328,794	43,254
(42) Charles N Petty Staff Physician	40				X		262,694	36,995
(43) Henry F Warden Executive Director, VIDD	40				X		261,812	39,064
(44) F Marc Stewart Medical Director, SCCA	40					X	197,371	37,179
(45) Rainier F Storb Full Member	40					X	247,218	57,436
(46) James M Roberts Full Member	40					X	148,155	35,145

(A) Name and business address	(B) Description of services	(C) Compensation
Seattle Cancer Care Alliance 825 Eastlake Ave E Seattle,WA98109	Patient care services	3,520,670
Metropolitan Building Maintenance Co 3829 Aurora Ave N Seattle,WA98103	Maintenance services	1,319,794
JP Morgan Chase Bank NA 1111 Polaris Parkway Columbus,OH43240	Letter of Credit fees	1,155,929
McKinsey and Company Inc 55 E 52nd St New York,NY10022	Consulting services	1,134,900
Bank of America 401 N Tryon St Charlotte,NC28255	Letter of Credit fees	1,060,776
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 in compensation from the organization 48

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the U.S. See Part IV, line 21	73,784,560	73,784,560
2	Grants and other assistance to individuals in the U.S. See Part IV, line 22	0	0
3	Grants and other assistance to governments, organizations, and individuals outside the U.S. See Part IV, lines 15 and 16	6,404,808	6,404,808
4	Benefits paid to or for members	0	0
5	Compensation of current officers, directors, trustees, and key employees ....	6,653,495	3,467,460	3,186,035	0
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) ....	0	0	0	0
7	Other salaries and wages	164,643,143	134,035,564	27,477,701	3,129,878
8	Pension plan contributions (include section 401(k) and section 403(b) employer contributions) ....	11,199,185	9,187,601	1,805,412	206,172
9	Other employee benefits .......	19,799,988	16,161,394	3,278,870	359,724
10	Payroll taxes ...........	11,924,364	9,608,576	2,105,449	210,339
11	Fees for services (non-employees):
a	Management ......	0	0	0	0
b	Legal .........	1,513,271	7,012	1,506,259	0
c	Accounting ...........	257,995	0	257,995	0
d	Lobbying ...........	118,859	0	118,859	0
e	Professional fundraising. See Part IV, line 17..	59,204			59,204
f	Investment management fees ......	1,032,945	0	1,032,945	0
g	Other ..........	22,522,933	11,939,125	10,189,026	394,782
12	Advertising and promotion ....	392,762	0	323,827	68,935
13	Office expenses .......	4,176,956	1,042,828	2,563,387	570,741
14	Information technology ......	1,044,952	0	1,044,952	0
15	Royalties ..	0	0	0	0
16	Occupancy ...........	6,882,880	117,312	6,765,568	0
17	Travel ............	2,592,397	2,151,648	319,382	121,367
18	Payments of travel or entertainment expenses for any federal, state, or local public officials ......	0	0	0	0
19	Conferences, conventions, and meetings ....	555,092	477,920	59,943	17,229
20	Interest ...........	13,511,373	12,565,577	945,796	0
21	Payments to affiliates .......	0	0	0	0
22	Depreciation, depletion, and amortization .....	25,147,092	22,158,566	2,988,526	0
23	Insurance ..............	1,573,949	0	1,573,949	0
24	Other expenses. Itemize expenses not covered above. (Expenses grouped together and labeled miscellaneous may not exceed 5% of total expenses shown on line 25 below.)
a	Research supplies	25,494,490	25,494,490	0	0
b	Equipment rental & maintenance	13,419,604	2,338,943	11,035,955	44,706
c	Allocation of indirect costs	0	63,383,467	-63,383,467	0
d
e
f	All other expenses	11,501,064	8,394,150	2,690,587	416,327
25	Total functional expenses. Add lines 1 through 24f	426,207,361	402,721,001	17,886,956	5,599,404
26	Joint costs. Check here if following SOP 98-2 (ASC 958-720). Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation

Part X Balance Sheet
	1	Cashnon-interest-bearing ..........	15,274	1	9,037
2	Savings and temporary cash investments .......	35,926,246	2	61,510,742
3	Pledges and grants receivable, net .........	32,217,752	3	34,026,493
4	Accounts receivable, net .........	18,479,708	4	18,046,009
5	Receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of
	Schedule L ..........		5
6	Receivables from other disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B). Complete Part II of
	Schedule L ..........		6
7	Notes and loans receivable, net .............	695,757	7	621,757
8	Inventories for sale or use ..............		8
9	Prepaid expenses and deferred charges ............	1,164,713	9	1,446,837
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	626,737,871
b	Less: accumulated depreciation. .....	10b	301,381,978	265,178,985	10c	325,355,893
11	Investments—publicly traded securities ..........	58,983,024	11	125,674,643
12	Investments—other securities. See Part IV, line 11 ......	48,090,908	12	40,827,536
13	Investments—program-related. See Part IV, line 11 ..	59,784,031	13	71,213,967
14	Intangible assets .........	0	14
15	Other assets. See Part IV, line 11 ...........	35,261,915	15	35,415,567
16	Total assets. Add lines 1 through 15 (must equal line 34)...	555,798,313	16	714,148,481
	17	Accounts payable and accrued expenses .	38,025,954	17	35,760,069
18	Grants payable ..........	0	18	0
19	Deferred revenue ..........	29,178,432	19	26,711,012
20	Tax-exempt bond liabilities ..........	266,607,522	20	372,159,052
21	Escrow or custodial account liability. Complete Part IV of Schedule D..	0	21	0
22	Payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........	0	22	0
23	Secured mortgages and notes payable to unrelated third parties ..	0	23	0
24	Unsecured notes and loans payable to unrelated third parties ....	0	24	0
25	Other liabilities. Complete Part X of Schedule D.....	28,981,141	25	26,486,011
26	Total liabilities. Add lines 17 through 25.....	362,793,049	26	461,116,144
		Organizations that follow SFAS 117, check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets .....	114,011,264	27	162,996,337
28	Temporarily restricted net assets .....	32,312,000	28	38,223,000
29	Permanently restricted net assets .....	46,682,000	29	51,813,000
	Organizations that do not follow SFAS 117, check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds .....		30
31	Paid-in or capital surplus, or land, building or equipment fund .....		31
32	Retained earnings, endowment, accumulated income, or other funds		32
33	Total net assets or fund balances .....	193,005,264	33	253,032,337
34	Total liabilities and net assets/fund balances .....	555,798,313	34	714,148,481

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section
4947(a)(1) nonexempt charitable trust.

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions

The organization is not a private foundation because it is: (For lines 1 through 11, check only one box.)

A church, convention of churches, or association of churches. section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E.)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in

section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in

section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross

receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of

its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses

acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. Seesection 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box that describes the type of supporting organization and complete lines 11e through 11h.

Type I

Type II

Type III - Functionally integrated

Type III - Other

By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2).

If the organization received a written determination from the IRS that it is a Type I, Type II or Type III supporting organization, check this box ..................................................

Since August 17, 2006, has the organization accepted any gift or contribution from any of the
following persons?

(i) a person who directly or indirectly controls, either alone or together with persons described in (ii)

Yes

and (iii) below, the governing body of the the supported organization? ................

11g(i)

(ii) a family member of a person described in (i) above? ......................

11g(ii)

(iii) a 35% controlled entity of a person described in (i) or (ii) above? ................

11g(iii)

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization in col. (i) listed in your governing document?		(v) Did you notify the organization in col. (i) of your support?		(vi) Is the organization in col. (i) organized in the U.S.?		(vii) Amount of support?
(i) Name of supported organization	(ii) EIN	Yes	No	Yes	No	Yes	No	(vii) Amount of support?


Total

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2010

Page 2

Part II

Support Schedule for Organizations Described in IRC 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year(or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") ....	301,287,235	322,118,651	309,139,679	345,010,973	387,997,752	1,665,554,290
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.......	0	0	0	0	0	0
3	The value of services or facilities furnished by a governmental unit to the organization without charge..	0	0	0	0	0	0
4	Total. Add lines 1 through 3..	301,287,235	322,118,651	309,139,679	345,010,973	387,997,752	1,665,554,290
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..						0
6	Public Support. Subtract line 5 from line 4.						1,665,554,290

Section B. Total Support

Calendar year(or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
7	Amounts from line 4..	301,287,235	322,118,651	309,139,679	345,010,973	387,997,752	1,665,554,290
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..	19,279,966	20,511,518	6,696,878	17,583,481	30,871,010	94,942,853
9	Net income from unrelated business activities, whether or not the business is regularly carried on..	0	18,779	-38,843	-62,064	-85,743	-167,871
10	Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets..	0	0	0	0	0	0
11	Total support (Add lines 7 through 10).						1,760,329,272

Gross receipts from related activities, etc. (See instructions.) ..................

First Five Years If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization,
check this box and stop here.......................................... right arrow

Section C. Computation of Public Support Percentage

Public Support Percentage for 2010 (line 6 column (f) divided by line 11 column (f)) .........

94.616 %

Public Support Percentage for 2009 Schedule A, Part II, line 14 ...............

95.228 %

16a

33 1/3% support test—2010. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ...................... right arrow

33 1/3% support test—2009. If the organization did not check the box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2010. If the organization did not check a box on line 13, 16a, or 16b and line 14
is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and stop here. Explain
in Part IV how the organization meets the "facts and circumstances" test. The organization qualifies as a publicly supported
organization .................................................. right arrow

10%-facts-and-circumstances test—2009. If the organization did not check a box on line 13, 16a, 16b, or 17a and line
15 is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and stop here.
Explain in Part IV how the organization meets the "facts and circumstances" test. The organization qualifies as a publicly
supported organization .............................................. right arrow

Private Foundation If the organization did not check a box on line 13, 16a, 16b, 17a or 17b, check this box and see
instructions ................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2010

Page 3

Part III

Support Schedule for Organizations Described in IRC 509(a)(2)
(Complete only if you checked the box on line 9 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year(or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose......
3	Gross receipts from activities that are not an unrelated trade or business under section 513..
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge..
6	Total. Add lines 1 through 5.
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons...
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public Support (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)
13	Total support (Add lines 9, 10c, 11 and 12.).

Section C. Computation of Public Support Percentage

Public Support Percentage for 2010 (line 8 column (f) divided by line 13 column (f)) .........

Public support percentage from 2009 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2010 (line 10c column (f) divided by line 13 column (f)) ......

Investment income percentage from 2009 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests—2010. If the organization did not check the box on line 14, and line 15 is more than 33 1/3% and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .......... right arrow

33 1/3% support tests—2009. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .... right arrow

Private Foundation If the organization did not check a box on line 14, 19a or 19b, check this box and see instructions ..... right arrow

Schedule A (Form 990 or 990-EZ) 2010

Page 4

Part IV

Supplemental Information. Supplemental Information. Complete this part to provide the explanation required by Part II, line 10; Part II, line 17a or 17b; or Part III, line 12. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Explanation

Schedule A (Form 990 or 990-EZ) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

OMB No. 1545-0047

2010

Name of organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note. Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, $5,000 or more (in money or
property) from any one contributor. Complete Parts I and II.

Special Rules

For a section 501(c)(3) organization filing Form 990 or 990-EZ, that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), and received from any one contributor, during the year, a contribution of the
greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For a section 501(c)(7), (8), or (10) organization filing Form 990, or 990-EZ, that received from any one contributor,
during the year, aggregate contributions of more than $1,000 for use exclusively for religious, charitable,
scientific, literary, or educational purposes, or the prevention of cruelty to children or animals. Complete Parts I, II, and
III.

For a section 501(c)(7), (8), or (10) organization filing Form 990, or 990-EZ, that received from any one contributor,
during the year, contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did
not aggregate to more than $1,000. If this box is checked, enter here the total contributions that were received during
the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the parts unless the General Rule
applies to this organization because it received nonexclusively religious, charitable, etc., contributions of $5,000 or more
during the year. ......................... Arrow Bullet

Caution. An Organization that is not covered by the General Rule and/or the Special Rules does not file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2 of its Form 990, or check the box in the heading of its
Form 990-EZ, or on line 2 of its Form 990-PF, to certify that it does not meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2010)

Name of organization FRED HUTCHINSON CANCER RESEARCH CENTER
Schedule B (Form 990, 990-EZ, or 990-PF) (2010) Page 1 of 1 of Part I
Part I	Contributors (see Instructions)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
RESTRICTED	RESTRICTED RESTRICTED RESTRICTED RESTRICTED, RESTRICTED RESTRICTED	$RESTRICTED	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Name of organization FRED HUTCHINSON CANCER RESEARCH CENTER
Schedule B (Form 990, 990-EZ, or 990-PF) (2010) Page 1 of 1 of Part II
Part II	Noncash Property (see Instructions)
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Page 1 of 1 of Part III

Name of organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part III

Exclusively religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations
aggregating more than $1,000 for the year. (Complete columns (a) through (e) and the following line entry.)
For organizations completing Part III, enter the total of exclusively religious, charitable, etc.,
contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

SCHEDULE C
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527
SchCMd Bullet

Complete if the organization is described below.
SchCMd Bullet

Attach to Form 990 or Form 990-EZ. SchCMd Bullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public
Inspection

If the organization answered “Yes,” to Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered “Yes,” to Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)) Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered “Yes,” to Form 990, Part IV, Line 5 (Proxy Tax) or Form 990-EZ, Part V, line 35a (Proxy Tax), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization's direct and indirect political campaign activities on behalf of or in opposition to candidates for public office in Part IV.

Political expenditures .................................... SchCMd Bullet

Volunteer hours ........................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ......... SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ...... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ..............

Yes No

Was a correction made? .........................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c) except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt funtion activities .................................... SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b.. SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ..........................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

For Privacy Act and Paperwork Reduction Act Notice, see the instructions for Form 990.

Cat. No. 50084S

Schedule C (Form 990 or 990-EZ) 2010

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check if the filing organization belongs to an affiliated group.
B Check if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing Organization's Totals	(b) Affiliated Group Totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......	0
b	Total lobbying expenditures to influence a legislative body (direct lobbying) .......	118,859
c	Total lobbying expenditures (add lines 1a and 1b) ...................	118,859
d	Other exempt purpose expenditures ........................	425,055,557
e	Total exempt purpose expenditures (add lines 1c and 1d) ...............	425,174,416
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................	250,000
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................	0
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................	0
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ......................................		Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the instructions for lines 2a through 2f on page 4.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2007	(b) 2008	(c) 2009	(d) 2010	(e) Total

2a	Lobbying non-taxable amount	1,000,000	1,000,000	1,000,000	1,000,000	4,000,000

b	Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000

c	Total lobbying expenditures	118,116	106,714	112,213	118,859	455,902

d	Grassroots non-taxable amount	250,000	250,000	250,000	250,000	1,000,000

e	Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000

f	Grassroots lobbying expenditures	0	0	0	0	0

Schedule C (Form 990 or 990-EZ) 2010

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

(a)

Yes

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? .........................................

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ....

Media advertisements? ....................................

Mailings to members, legislators, or the public? .........................

Publications, or published or broadcast statements? .......................

Grants to other organizations for lobbying purposes? .......................

Direct contact with legislators, their staffs, government officials, or a legislative body? ........

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ......

Other activities? If "Yes," describe in Part IV ..........................

Total. lines 1c through 1i ...................................

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 .................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 .....

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? .......

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ................

Did the organization agree to carryover lobbying and political expenditures from the prior year? ..........

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) if BOTH Part III-A, lines 1 and 2 are answered “No” OR if Part III-A, line 3 is answered “Yes”.

Dues, assessments and similar amounts from members .....................

Section 162(e) non-deductible lobbying and political expenditures (do not include amounts of political
expenses for which the section 527(f) tax was paid).

Current year .........................................

Carryover from last year ....................................

Total ...........................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ................................

Taxable amount of lobbying and political expenditures (see instructions) ..............

Part IV

Supplemental Information

Complete this part to provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; and Part ll-B, line 1i.
Also, complete this part for any additional information.

Identifier	Return Reference	Explanation

Schedule C (Form 990 or 990EZ) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," to Form 990,
Part IV, line 6, 7, 8, 9, 10, 11, or 12.
SchDMd Bullet

Attach to Form 990. SchDMd Bullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .......
2	Aggregate contributions to (during year) ...
3	Aggregate grants from (during year) ...
4	Aggregate value at end of year .......

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised
funds are the organization's property, subject to the organization's exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds may be
used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit. ...................................

Yes No

Part II

Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or pleasure) Preservation of an historically importantly land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a–2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements .......................	2a
b	Total acreage restricted by conservation easements ..................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 8/17/06 ........	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during
the taxable year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and
enforcement of the conservation easements it holds? .............................

Yes No

Staff and volunteer hours devoted to monitoring, inspecting and enforcing conservation easements during the year SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section
170(h)(4)(B)(i) and 170(h)(4)(B)(ii)? ....................................

Yes No

In Part XIV, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

If the organization elected, as permitted under SFAS 116, not to report in its revenue statement and balance sheet works of
art, historical treasures, or other similar assets held for public exhibition, education or research in furtherance of public service,
provide, in Part XIV, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under SFAS 116, to report in its revenue statement and balance sheet works of art,
historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service,
provide the following amounts relating to these items:

(i)

Revenues included in Form 990, Part VIII, line 1 ........................ SchDMd Bullet

$ 0

(ii)

Assets included in Form 990, Part X .............................. SchDMd Bullet

$ 710,646

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under SFAS 116 relating to these items:

Revenues included in Form 990, Part VIII, line 1 .......................... SchDMd Bullet

$ 0

Assets included in Form 990, Part X ............................... SchDMd Bullet

$ 0

For Privacy Act and Paperwork Reduction Act Notice, see the Intructions for Form 990

Cat. No. 52283D

Schedule D (Form 990) 2010

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s accession and other records, check any of the following that are a significant use of its collection
items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other Per Donor Restriction, must maintain until 2030

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIV.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?........

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990,
Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No

If "Yes," explain the arrangement in Part XIV and complete the following table:


c	Beginning balance .................................	1c
d	Additions during the year ..............................	1d
e	Distributions during the year .............................	1e
f	Ending balance ...................................	1f

Did the organization include an amount on Form 990, Part X, line 21? .....................

Yes No

If “Yes,” explain the arrangement in Part XIV.

Part V

Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

		(a)Current Year	(b)Prior Year	(c)Two Years Back
1a	Beginning of year balance ....	82,001,707	75,830,000	100,751,000
b	Contributions ........	14,234,000	5,559,524	4,053,000
c	Investment earnings or losses ...	14,988,000	7,831,043	-18,913,000
d	Grants or scholarships .....	0	0	0
e	Other expenditures for facilities and programs ........	16,994,000	7,218,860	10,061,000
f	Administrative expenses ....	0	0	0
g	End of year balance ......	94,229,707	82,001,707	75,830,000

Provide the estimated percentage of the year end balance held as:

Board designated or quasi-endowment: SchDMd Bullet

68 %

Permanent endowment: SchDMd Bullet

26 %

Term endowment: SchDMd Bullet

6 %

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) unrelated organizations ........................

3a(i)

(ii) related organizations ........................

3a(ii)

If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIV the intended uses of the organization's endowment funds.

Part VI

InvestmentsLand, Buildings, and Equipment. See Form 990, Part X, line 10.

Description of investment		(a) Cost or other basis (investment)	(b)Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a	Land .................	0	52,389,138		52,389,138
b	Buildings ................	0	376,821,746	217,559,101	159,262,645
c	Leasehold improvements ............	0	0	0	0
d	Equipment ................	0	164,346,906	83,822,877	80,524,029
e	Other .................	0	33,180,081	0	33,180,081
Total. Add lines 1a-1e. (Column (d) should equal Form 990, Part X, column (B), line 10(c).)........					325,355,893

Schedule D (Form 990) 2010

Page 3

Part VII

InvestmentsOther Securities. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b)Book value	(c) Method of valuation: Cost or end-of-year market value
(1)Financial derivatives
(2)Closely-held equity interests
(3)Other (A) Mortgage-Backed Securities	1,868,768	F
(B) Collaterized Mortgage Oblig	371,278	F
(C) Asset Backed Securities	195,060	F
(D) Hedge Funds	4,736,728	F
(E) Limited Partnerships	22,991,634	F
(F) Ikaria Stock	9,837,185	F
(G) Other	826,883	F


Total. (Column (b) should equal Form 990, Part X, col.(B) line 12.)	40,827,536

Part VIII

InvestmentsProgram Related. See Form 990, Part X, line 13.

(a) Description of investment type	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Investment in Seattle Cancer Care Alliance	71,213,967	C








Total. (Column (b) should equal Form 990, Part X, col.(B) line 13.)	71,213,967

Part IX

Other Assets. See Form 990, Part X, line 15.

(a) Description				(b) Book value
(1) Beneficial Interest in Perpetual Trusts				27,330,741
(2) Rental Property				5,555,444
(3) Deferred Financing Costs				2,530,782
(4) Others				-1,400





Total. (Column (b) should equal Form 990, Part X, col.(B) line 15.)...........				35,415,567

Part X

Other Liabilities. See Form 990, Part X, line 25.

1.(a) Description of Liability		(b) Amount
Federal Income Taxes
Deferred Credit Cash Flow Hedge		26,486,011








Total. (Column (b) should equal Form 990, Part X, col.(B) line 25.)		26,486,011
2. Fin 48 (ASC 740) Footnote. In Part XIV, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC740).

Schedule D (Form 990) 2010

Page 4

Part XI Reconciliation of Change in Net Assets from Form 990 to Financial Statements
1	Total revenue (Form 990, Part VIII, column (A), line 12) ....................	1	470,606,324
2	Total expenses (Form 990, Part IX, column (A), line 25) .....................	2	426,207,361
3	Excess or (deficit) for the year. Subtract line 2 from line 1 .............	3	44,398,963
4	Net unrealized gains (losses) on investments ..........................	4	13,133,181
5	Donated services and use of facilities .............................	5	0
6	Investment expenses ...................................	6	0
7	Prior period adjustments ..................................	7	0
8	Other (Describe in Part XIV) .................................	8	2,494,930
9	Total adjustments (net). Add lines 4 - 8 .............................	9	15,628,111
10	Excess or (deficit) for the year per financial statements. Combine lines 3 and 9 .........	10	60,027,074

Part XII Reconciliation of Revenue per Audited Financial Statements With Revenue per Return
1	Total revenue, gains, and other support per audited financial statements .......			1	469,573,378
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains on investments ..........	2a	0
b	Donated services and use of facilities .........	2b	0
c	Recoveries of prior year grants ...........	2c	0
d	Other (Describe in Part XIV): ............	2d	0
e	Add lines 2a through 2d .....................			2e	0
3	Subtract line 2e from line 1.....................			3	469,573,378
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	1,032,946
b	Other (Describe in Part XIV): ...........	4b	0
c	Add lines 4a and 4b.......................			4c	1,032,946
5	Total Revenue. Add lines 3 and 4c. (This should equal Form 990, Part I, line 12.) ......			5	470,606,324

Part XIII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return
1	Total expenses and losses per audited financial statements .............			1	425,174,416
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities ..........	2a	0
b	Prior year adjustments ..............	2b	0
c	Other losses ................	2c	0
d	Other (Describe in Part XIV): ............	2d	0
e	Add lines 2a through 2d......................			2e	0
3	Subtract line 2e from line 1.....................			3	425,174,416
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a	1,032,945
b	Other (Describe in Part XIV): ............	4b	0
c	Add lines 4a and 4b.......................			4c	1,032,945
5	Total expenses. Add lines 3 and 4c. (This should equal Form 990, Part I, line 18.) ......			5	426,207,361

Part XIV

Supplemental Information

Complete this part to provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b;
Part V, line 4; Part X; Part XI, line 8; Part XII, lines 2d and 4b; and Part XIII, lines 2d and 4b. Also complete this part to provide any additional information.

Identifier	Return Reference	Explanation
SchD_P03_S00_L04	Schedule D, Part III, Line 4	In January 2010, the QTIP Trust of the 1993 Kullman Family Trust donated to the Center a collection of forty black and white photographs which had an appraised value of $710,646 at the time of the donation. The Artwork Donation Agreement requires the Center to display the Artwork as a collection at its main campus in Seattle, Washington for at least twenty years. The Artwork Donation Agreement states that "the Center shall have the right to use and display the Artwork in the manner that best serves the interest of the Center." At the end of the required twenty year display period, the Center will determine if opportunities exist that may allow the value of the donated artwork to fund the Center's research.
SchD_P05_S00_L04	Schedule D, Part V, Line 4	Spending Policy - The Center's spending policy for endowment funds is to appropriate for distribution each year 5% percent of the endowment fund's average fair value over the prior three years, provided that the fair value of the endowment fund exceeds the corpus. For a portion of the Center's Board-designated investments, the Center does not appropriate for distribution any amount of investment return as all of the return earned is held to grow the fund for future repayment of long-term debt. For the remaining board designated investments, the Center makes all investment return available for expenditure on programmatic initiatives. In establishing these policies, the Center considered the long-term expected returns on its endowment and Board-designated investments.
SchD_P11_S00_L08	Schedule D, Part XI, Line 8	Change in net unrealized fair value of swap instruments.

Schedule D (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

SCHEDULE F
(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990,
Part IV, line 14b, 15, or 16.
Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

General Information on Activities Outside the United States. Complete if the organization answered
“Yes” to Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of the grants or

assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award

the grants or assistance? ...................................

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of grant funds outside the
United States.

Activites per Region. (Use Part V if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees or agents in region or independent contractors	(d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for region/investments in region
	Central America and the Caribbean	0	0	Grantmaking	N/A	719,111
	East Asia and the Pacific	0	0	Grantmaking	N/A	142,614
	Europe (including Iceland and Greenland)	0	0	Grantmaking	N/A	1,550,858
	North America (including Canada and Mexico, but not the United States)	0	0	Grantmaking	N/A	850,758
	South America	0	0	Grantmaking	N/A	521,874
	Sub-Saharan Africa	0	0	Grantmaking	N/A	1,989,083
	Sub-Saharan Africa	0	1	Program Services	Research	71,427










3a	Sub-total .....
b	Total from continuation sheets to Part I ...
c	Totals (add lines 3a and 3b)	0	1			5,845,725

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2010

Schedule F (Form 990) 2010

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" to Form 990,

Part IV, line 15, for any recipient who received more than $5,000. Check this box if no one recipient received more than $5,000 ........ MediumBullet

Use Part V if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
Central America and the Caribbean	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	566,941	Wire transfer	N/A	N/A
Central America and the Caribbean	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	152,170	Wire transfer	N/A	N/A
East Asia and the Pacific	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI	142,614	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI	23,052	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI	9,609	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR	186,153	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	HVTN LABORATORY PROGRAM	169,981	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PR	150,036	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	682,561	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING,	197,807	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	THE PATHOGENESIS OF FMD: FACIOSCAPULOHUMERAL MUSCULAR	105,504	Wire transfer	N/A	N/A
Europe (including Iceland and Greenland)	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI	26,156	Wire transfer	N/A	N/A
North America (including Canada and Mexico, but not the United States)	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI	57,918	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CA	38,246	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	EXPANSION OF CARDIAC AND HEMATOPOIETIC PREGENITORS BY WN	167,485	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	HVTN LABORATORY PROGRAM	14,173	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	THE GENETICS OF PARALLEL REPRODUCTIVE ISOLATION IN STICK	30,722	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	THE PACIFIC NORTHWEST PROSTATE CANCER SPORE	307,340	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOM	82,994	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	TREC: MECHANISMS OF ENERGY BALANCE AND CANCER PREVENTION	7,402	Check	N/A	N/A
North America (including Canada and Mexico, but not the United States)	WASHINGTON VACCINE ALLIANCE	144,477	Check	N/A	N/A
South America	BREAST HEALTH GLOBAL INITIATIVE	21,400	Wire transfer	N/A	N/A
South America	IMPROVING BREAST CANCER SCREENING AT THE PRIMARY CARE LE	17,246	Wire transfer	N/A	N/A
South America	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	279,649	Wire transfer	N/A	N/A
South America	READINESS ASSESSMENT FOR IMPLEMENTATION OF BREAST CANCER	5,376	Wire transfer	N/A	N/A
South America	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	198,203	Wire transfer	N/A	N/A
Sub-Saharan Africa	EARLY AND REINFECTION IN HIGH RISK WOMEN	43,111	Wire transfer	N/A	N/A
Sub-Saharan Africa	HVTN LABORATORY PROGRAM	248,294	Wire transfer	N/A	N/A
Sub-Saharan Africa	HVTN LABORATORY PROGRAM	594,430	Wire transfer	N/A	N/A
Sub-Saharan Africa	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	45,946	Check	N/A	N/A
Sub-Saharan Africa	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	193,577	Wire transfer	N/A	N/A
Sub-Saharan Africa	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	351,175	Wire transfer	N/A	N/A
Sub-Saharan Africa	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	13,500	Wire transfer	N/A	N/A
Sub-Saharan Africa	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	5,037	Wire transfer	N/A	N/A
Sub-Saharan Africa	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	418,842	Wire transfer	N/A	N/A
Sub-Saharan Africa	ADULT LEUKEMIA RESEARCH CENTER	22,150	Wire transfer	N/A	N/A
Sub-Saharan Africa	IMPACT OF HIV AND HHV-8 CO-INFECTION ON ANTIRETROVIRAL T	33,921	Wire transfer	N/A	N/A
Sub-Saharan Africa	ASSOCIATION BETWEEEN HIV AND SURVIVAL AFTER CANCER DIAGN	15,006	Wire transfer	N/A	N/A

Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter ..... MediumBullet

Enter total number of other organizations or entities ........................ MediumBullet

Schedule F (Form 990) 2010

Schedule F (Form 990) 2010Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.

Use Part V if additional space is needed.

	(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(g) Description of non-cash assistance	(h) Method of valuation (book, FMV, appraisal, other)
Airfare	Central America and the Caribbean	1	1,093	Check	N/A	N/A
Airfare	East Asia and the Pacific	1	101,423	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	East Asia and the Pacific	1	26,030	Check	N/A	N/A
Airfare	Europe (including Iceland and Greenland)	1	121,277	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	Europe (including Iceland and Greenland)	1	39,425	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	Europe (including Iceland and Greenland)	1	2,222	Wire	N/A	N/A
Airfare	Middle East and North Africa	1	2,110	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	Middle East and North Africa	1	526	Check	N/A	N/A
Airfare	North America (including Canada and Mexico, but not the United States)	1	16,923	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	North America (including Canada and Mexico, but not the United States)	1	4,693	Check	N/A	N/A
Airfare	Russia and the newly independent States	1	13,777	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	Russia and the newly independent States	1	10,684	Check	N/A	N/A
Airfare	South America	1	22,519	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	South America	1	2,531	Check	N/A	N/A
Airfare	South Asia	1	4,330	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	South Asia	1	360	Check	N/A	N/A
Airfare	Sub-Saharan Africa	1	166,160	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	Sub-Saharan Africa	1	22,086	Check	N/A	N/A
Travel costs (e.g. lodging, meals, incidentals, etc.)	Sub-Saharan Africa	1	914	Wire	N/A	N/A

Schedule F (Form 990) 2010

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2010

Page 5

Part V

Supplemental Information
Complete this part to provide the information (see instructions) required in Part I, line 2, and any additional information.

Identifier	ReturnReference	Explanation
SchF_P01_S00_L02	Schedule F, Part I, Line 2	Procedure for Monitoring the Use of Grant Funds Once the notice of award has been received and the Center project ID activated, the subaward can be set up. The structure of the subaward will depend on how the Prime is set up. Generally at the Center, a new PO is requisitioned for each subaward for each year of a project. This allows the RC to closely monitor subaward invoices and encumbrances. For our Subrecipients, it means a separate budget ID and final invoice each year. Carryover between years is not automatic. There are 5 primary steps. 1) Step one is within OSR. The Grant Specialist notifies the Contract Specialist that a grant which includes a subaward has been funded, and provides to the Contract Specialist a copy of the award, the signed subaward application (if available) and any special instructions. A signed subaward application is important because it shows that the Subrecipient organization has reviewed and approved the budget and scope of work. 2) The Research Coordinator (RC) sends the Contract Specialist a Subcontract Acquisition Form (SAF). This form provides authorization for the Contract Specialist to issue the subaward, and included a scope of work, budget and pertinent subrecipient information. It is necessary to provide the scope of work and budget on the SAF as these items may have changed from what was originally submitted in the subaward application. 3) The Contract Specialist requisitions the subaward PO, which the RC must approve. An e-mail is sent to the RC notifying them that the requisition is pending and requires approval. Because OSR does not have funds commitment authority the RC is required to approve all requisition. 4) OSR collects information required to correctly set up the subaward. These items include IRO and IACUC approval dates, confirmation of subaward F&A rates and A-133 Audit reports, review of Prime special terms and conditions to determine flow-down, confirmation that the Subrecipients is not debarred, and other similar regulatory and administrative requirements. While much of this information is collected by OSR, the RC may, in addition to completing the SAF, be asked to assist in the collection of some of the documentation. 5) OSR writes the subaward agreement, and mails it to the Subrecipients for signature. Some agreements can be signed by OSR before mailing, while others will be sent unsigned. This is determined by the Contract Specialist based on the terms of award and status of administrative and regulatory requirements. A copy of the initial subaward is sent to the RC. Once the subaward has been fully signed, a copy is sent to the RC for their files. No invoices should be approved by the RC until they have received a fully executed agreement.
SchF_P04_S00_L00	Schedule F, Part IV	Schedule F, Part III, Number of Recipients - The data presented above are employee incurred foreign travel costs which we believe meet the IRS Schedule F, Part III's request for grants and other assistance to "U.S. individuals for foreign activity." As such, column (c)'s request for "the number of recipients that received the type of assistance in that region" does not appear to apply foreign travel cost incurred by U.S. individuals.

Schedule F (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

SCHEDULE G
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" to Form 990, Part IV, lines 17, 18, or 19,
or if the organization entered more than $15,000 on Form 990-EZ, line 6a.
right arrow

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

Fundraising Activities. Complete if the organization answered "Yes" to Form 990, Part IV, line 17.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and e-mail solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

Yes

If “Yes,” list the ten highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization. Form 990-EZ filers are not required to complete this table.

(i) Name and address of individual or entity (fundraiser)	(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
	(ii) Activity	Yes	No	(iv) Gross receipts from activity		(vi) Amount paid to (or retained by) organization
Lewis Kennedy Associates Inc PO Box 3257 Portland, OR97208	Direct Mail		No	600,983	59,204	541,779
Total .................				600,983	59,204	541,779

List all states in which the organization is registered or licensed to solicit funds or has been notified it is exempt from registration or licensing.

AK, AL, AR, AZ, CA, CO, CT, FL, GA, HI, IL, KS, KY, MA, MD, ME, MI, MN, MO, MS, NC, ND, NH, NJ, NM, NY, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WI, WV

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50083H

Schedule G (Form 990 or 990-EZ) 2010

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" to Form 990, Part IV, line 18, or reported more than $15,000 on Form 990-EZ, line 6a. List events with gross receipts greater than $5,000.

		(a) Event #1 Hutch Holiday Gala (event type)	(b) Event #2 Climb to Fight Breast Cancer (event type)	(c) Other Events 7 (total number)	(d) Total Events (Add col. (a) through col. (c))
1	Gross receipts . . .	6,131,259	459,796	1,345,896	7,936,951
2	Less: Charitable contributions . . .	5,798,259	459,796	1,158,231	7,416,286
3	Gross income (line 1 minus line 2) . . .	333,000	0	187,665	520,665
4	Cash prizes . . .	0	0	0	0
5	Non-cash prizes . .	0	0	0	0
6	Rent/facility costs . .	0	0	0	0
7	Food and beverages . .	193,881	0	87,728	281,609
8	Entertainment . . .	33,123	0	26,186	59,309
9	Other direct expenses .	195,027	309,833	134,135	638,995
10	Direct expense summary. Add lines 4 through 9 in column (d) ...........				979,913
11	Net income summary. Combine lines 3 and 10 in column (d)............				-459,248

Part III

Gaming. Complete if the organization answered "Yes" to Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

(a) Bingo

(b) Pull tabs/Instant
bingo/progressive bingo

(c) Other gaming

(d) Total gaming (Add col. (a) through col. (c))

Gross revenue . . . .

Cash prizes . . . .

Non-cash prizes . . .

Rent/facility costs . . .

Other direct expenses . .

Volunteer labor . . .

	Yes
	No

	Yes
	No

	Yes
	No

Direct expense summary. Add lines 2 through 5 in column (d) ........... right arrow

Net gaming income summary. Combine lines 1 and 7 in column (d) .......... right arrow

Enter the state(s) in which the organization operates gaming activities:

Is the organization licensed to operate gaming activities in each of these states? ............

YesNo

If "No," Explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? .....

YesNo

If "Yes," Explain:

Does the organization operate gaming activities with nonmembers? .................

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? ...........................

YesNo

Schedule G (Form 990 or 990-EZ) 2010

Page 3

Indicate the percentage of gaming activity operated in:

The organization's facility ......................

13a

An outside facility ........................

13b

Provide the name and address of the person who prepares the organization's gaming/special events books and records:

Name

Address

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? ......................................

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address:

Name

Address

Gaming manager information:

Name

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? ............................

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Complete this part to provide additional information for responses to quuestion on Schedule G (see instructions.)

Identifier	ReturnReference	Explanation

Schedule G (Form 990 or 990-EZ) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number
23-7156071

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ....................................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to
Form 990, Part IV, line 21 for any recipient that received more than $5,000. Check this box if no one recipient received more than $5,000. Use
Part IV and Schedule I-1 (Form 990) if additional space is needed ......................... lBullet

(a) Name and address of organization or government	(b) EIN	(c) IRC Code section if applicable	(d) Amount of cash grant	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
(1) ADMINISTRATORS OF THE TULANE800 EAST COMMERCE RD SUITE 203 HARAHAN,LA70123	72-0423889	501(c)(3)	62,631	N/A	N/A	HVTN LABORATORY PROGRAM
(2) AIDS RESEARCH ALLIANCE OF AMERICA1400 S GRAND AVE SUITE 701 LOS ANGELES,CA90015	95-4264845	501(c)(3)	988,421	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(3) BATTELLE MEMORIAL INSTITUTE ATTN CASHIERP O BOX 84262 SEATTLE,WA981245562	31-4379427	501(c)(3)	49,042	N/A	N/A	RADIATION DOSE-DEPENDENT INTERVENTIONS
(4) BATTELLE MEMORIAL INSTITUTE ATTN CASHIERP O BOX 84262 SEATTLE,WA981245562	31-4379427	501(c)(3)	719,398	N/A	N/A	IMPROVING EARLY DETECTION OF BREAST CANCER WITH A BLOOD
(5) BATTELLE MEMORIAL INSTITUTE ATTN CASHIERP O BOX 84262 SEATTLE,WA981245562	31-4379427	501(c)(3)	8,791	N/A	N/A	BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM - SUPPLEMEN
(6) BATTELLE MEMORIAL INSTITUTE ATTN CASHIERP O BOX 84262 SEATTLE,WA981245562	31-4379427	501(c)(3)	62,791	N/A	N/A	THE BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM- PHASE
(7) BAYLOR COLLEGE OF MEDICINEBCM280 ONE BAYLOR PLAZA HOUSTON,TX77030	74-1613878	501(c)(3)	732,992	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(8) BAYLOR COLLEGE OF MEDICINE OFFICE OF GRANTS & CONTRACTSBCM 206 ONE BAYLOR PLAZA HOUSTON,TX77030	74-1613878	501(c)(3)	31,613	N/A	N/A	CORE ASSAYS MRLI - W1 W3
(9) BAYSTATE MEDICAL CENTER INCP O BOX 414168 BOSTON,MA022414168	04-2790311	501(c)(3)	14,700	N/A	N/A	A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L
(10) BECKMAN RESEARCH INSTITUTE OF THE1500 EAST DUARTE ROAD DUARTE,CA910103012	95-3432210	501(c)(3)	18,054	N/A	N/A	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI
(11) BECKMAN RESEARCH INSTITUTE OF THE1500 EAST DUARTE ROAD DUARTE,CA910103012	95-3432210	501(c)(3)	14,074	N/A	N/A	TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMOR
(12) BENAROYA RESEARCH INSTITUTE1201 NINTH AVE SEATTLE,WA98101	91-0653422	501(c)(3)	89,657	N/A	N/A	MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS
(13) BENAROYA RESEARCH INSTITUTE1201 NINTH AVE SEATTLE,WA98101	91-0653422	501(c)(3)	42,099	N/A	N/A	HEMATOPOIETIC CELL TRANSPLANTATION AND IRON OVERLOAD
(14) BETH ISRAEL DEACONESS MEDICAL CENTER RESEARCH FINANCE OFFICE BR 109330 BROOKLINE AVENUE ROOM 262 BOSTON,MA02215	04-2103881	501(c)(3)	48,998	N/A	N/A	HVTN LABORATORY PROGRAM
(15) BOARD OF TRUSTEES OF THE LELANDP O BOX 44253 SAN FRANCISCO,CA941444253	94-1156365	501(c)(3)	55,407	N/A	N/A	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD
(16) BOARD OF TRUSTEES OF THE LELANDP O BOX 44253 SAN FRANCISCO,CA941444253	94-1156365	501(c)(3)	10,191	N/A	N/A	STATISTICAL METHODS FOR INTEGRATIVE ANALYSIS OF GENOMICS
(17) BOARD OF TRUSTEES OF THE LELANDP O BOX 44253 SAN FRANCISCO,CA941444253	94-1156365	501(c)(3)	74,861	N/A	N/A	IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC
(18) BOARD OF TRUSTEES OF THE LELANDP O BOX 44253 SAN FRANCISCO,CA941444253	94-1156365	501(c)(3)	126,914	N/A	N/A	PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM
(19) BOARD OF TRUSTEES OF THE LELANDP O BOX 44253 SAN FRANCISCO,CA941444253	94-1156365	501(c)(3)	149,586	N/A	N/A	CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)
(20) BOARD OF TRUSTEES UNIVERSITY OF ILLINOIS GRANTS & CONTRACTSP O BOX 20787 SPRINGFIELD,IL627080787	37-6000511	University	8,615	N/A	N/A	HVTN LABORATORY PROGRAM
(21) BOARD OF TRUSTEES UNIVERSITY OF ILLINOIS GRANTS & CONTRACTSP O BOX 20787 SPRINGFIELD,IL627080787	37-6000511	University	1,146,649	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(22) BRIGHAM AND WOMENS HOSPITAL INC BANK OF AMERICA NAP O BOX 3887 FINANCE BOSTON,MA022413887	04-2312909	501(c)(3)	947,595	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(23) BRIGHAM AND WOMENS HOSPITAL INC BANK OF AMERICA NAP O BOX 3887 FINANCE BOSTON,MA022413887	04-2312909	501(c)(3)	118,798	N/A	N/A	BIOCONDUCTOR- AN OPEN COMPUTING RESOURCE FOR GENOMICS
(24) BRIGHAM AND WOMENS HOSPITAL INC BANK OF AMERICA NAP O BOX 3887 FINANCE BOSTON,MA022413887	04-2312909	501(c)(3)	76,069	N/A	N/A	BARRETT'S ESOPHAGUS- PREDICTORS OF PROGRESSION
(25) BRIGHAM AND WOMENS HOSPITAL INC BANK OF AMERICA NAP O BOX 3887 FINANCE BOSTON,MA022413887	04-2312909	501(c)(3)	176,148	N/A	N/A	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR
(26) BRIGHAM AND WOMENS HOSPITAL INC BANK OF AMERICA NAP O BOX 3887 FINANCE BOSTON,MA022413887	04-2312909	501(c)(3)	1,061,377	N/A	N/A	GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS IN C
(27) BROAD INSTITUTE INC CASH MANAGER7 CAMBRIDGE CENTER OFFICE 7112L CAMBRIDGE,MA02142	26-3428781	501(c)(3)	998,654	N/A	N/A	IMPROVING EARLY DETECTION OF BREAST CANCER WITH A BLOOD
(28) BROAD INSTITUTE INC ATTN AMY GALAVIZ7 CAMBRIDGE CENTER CAMBRIDGE,MA02142	26-3428781	501(c)(3)	681,793	N/A	N/A	MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS IN C
(29) BROAD INSTITUTE INC CASH MANAGER7 CAMBRIDGE CENTER OFFICE 7112L CAMBRIDGE,MA02142	26-3428781	501(c)(3)	1,095,058	N/A	N/A	GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS IN C
(30) BROAD INSTITUTE INC CASH MANAGER7 CAMBRIDGE CENTER OFFICE 7112L CAMBRIDGE,MA02142	26-3428781	501(c)(3)	36,585	N/A	N/A	BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM - SUPPLEMEN
(31) BROAD INSTITUTE INC CASH MANAGER7 CAMBRIDGE CENTER OFFICE 7112L CAMBRIDGE,MA02142	26-3428781	501(c)(3)	248,585	N/A	N/A	THE BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM- PHASE
(32) CALIFORNIA RURAL INDIAN HEALTH BOARD INC4400 AUBURN BLVD 2ND FLOOR SACRAMENTO,CA95841	23-7052541	501(c)(3)	49,485	N/A	N/A	A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMON
(33) CANCER RESEARCH AND BIOSTATISTICS1730 MINOR AVENUE SUITE 1900 SEATTLE,WA981011468	91-1828539	501(c)(3)	2,681,979	N/A	N/A	SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER
(34) CANCER RESEARCH AND BIOSTATISTICS1730 MINOR AVENUE SUITE 1900 SEATTLE,WA981011468	91-1828539	501(c)(3)	151,771	N/A	N/A	CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER
(35) CASE WESTERN RESERVE UNIVERSITY OFFICE OF SPONSORED PROJECTS ACCOUNTING10900 EUCLID AVE CLEVELAND,OH441067037	34-1018992	501(c)(3)	207,949	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(36) CASE WESTERN RESERVE UNIVERSITY OFFICE OF SPONSORED PROJECTS ACCOUNTING10900 EUCLID AVE CLEVELAND,OH441067037	34-1018992	501(c)(3)	114,325	N/A	N/A	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS
(37) CEDARS SINAI MEDICAL CENTER SPONSORED RESEARCH & FUNDS ADMINISTRATION8700 BEVERLY BLVD SUITE 1150 65-WIL LOS ANGELES,CA900481865	95-1644600	501(c)(3)	97,555	N/A	N/A	PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM
(38) CENTER FOR MEDICAL TECHNOLOGY POLICY WORLD TRADE CENTER BALTIMORE401 EAST PRATT STREET SUITE 631 BALTIMORE,MD21202	26-1409553	501(c)(3)	252,366	N/A	N/A	CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER
(39) CHILDREN'S HOSPITAL MEDICAL CENTER DBA ACCOUNTING OFFICE MLC-50003333 BURNET AVENUE CINCINNATI,OH452293039	31-0833936	501(c)(3)	114,764	N/A	N/A	DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIE
(40) CITY AND COUNTY OF SAN FRANCISCO1380 HOWARD ST RM 417 SAN FRANCISCO,CA94103	94-6000417	CITY-CNTY OF SF	296,975	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(41) CITY OF PHILADELPHIA1401 JFK BLVD ROOM 1380 MSB PHILADELPHIA,PA19102	23-6003047	CITY OF PHILADELPHIA	62,443	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HIV PR
(42) CLINICAL ALLIANCE FOR RESEARCH AND3289 WOODBURN ROAD SUITE 250 ANNANDALE,VA22003	20-2651141		178,847	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(43) COLORADO STATE UNIVERSITY CASHIER'S OFFICE6015 CAMPUS DELIVERY - OSP FORT COLLINS,CO805236015	84-6000545	University	146,595	N/A	N/A	TREC- MECHANISMS OF ENERGY BALANCE AND CANCER PREVENTION
(44) COMSYS INFO TECHNOLOGY SERVICES LLCP O BOX 60260 CHARLOTTE,NC28260	75-1300240		212,450	N/A	N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT
(45) CORNELL UNIVERSITYP O BOX 22 ITHACA,NY148510022	15-0532082	501(c)(3)	129,829	N/A	N/A	TOWARDS A MODEL OF FANCONI ANEMIA
(46) DANA FARBER CANCER INSTITUTE RESEARCH ACCOUNTING450 BROOKLINE AVENUE MAIL STOP BP451 BOSTON,MA02215	04-2263040	501(c)(3)	39,754	N/A	N/A	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD
(47) DANA FARBER CANCER INSTITUTE MED ONCOLOGY GMOLW 258 BOSTON,MA02215	04-2263040	501(c)(3)	97,500	N/A	N/A	BLOOD TESTS FOR THE EARLY DETECTION OF LUNG CANCER
(48) DISTRICT OF COLUMBIA GOV-DC TREASURY899 NORTH CAPITOL NE 4TH FLOOR WASHINGTON,DC20002	53-6001131	DISTRICT OF COLUMBIA	629,591	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HIV PR
(49) DUKE UNIVERSITY OFFICE OF SPONSORED PROGRAMS2200 WEST MAIN STREET SUITE 300 DURHAM,NC277054677	56-0532129	501(c)(3)	2,138,648	N/A	N/A	HVTN LABORATORY PROGRAM
(50) DUKE UNIVERSITY OFFICE OF SPONSORED PROGRAMS2200 WEST MAIN STREET SUITE 300 DURHAM,NC277054677	56-0532129	501(c)(3)	31,274	N/A	N/A	MECHANISM-BASED CLASSIFICATION AND TARGETING OF CASTRATI
(51) EMORY UNIVERSITY GRANTS & CONTRACTS ACCOUNTING1599 CLIFTON ROAD NE 4TH FLOOR MS 1599-001-1BH ATLANTA,GA303224250	58-0566256	501(c)(3)	597,689	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(52) EMORY UNIVERSITY GRANTS & CONTRACTS ACCOUNTING1599 CLIFTON ROAD NE 4TH FLOOR MS 1599-001-1BH ATLANTA,GA303224250	58-0566256	501(c)(3)	799,367	N/A	N/A	HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OF
(53) EMORY UNIVERSITY GRANTS & CONTRACTS ACCOUNTING1599 CLIFTON ROAD NE 4TH FLOOR MS 1599-001-1BH ATLANTA,GA303224250	58-0566256	501(c)(3)	132,381	N/A	N/A	CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES
(54) EXPONENT INCP O BOX 200283 DEPT 002 DALLAS,TX753200283	77-0218904		10,500	N/A	N/A	THE FEASIBILITY OF EARLIER DETECTION OF OVARIAN CANCER U
(55) FENWAY COMMUNITY HEALTH FINANCE1340 BOYLSTON ST 9TH FLOOR BOSTON,MA02215	04-2510564	501(c)(3)	866,490	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(56) FENWAY COMMUNITY HEALTH FINANCE1340 BOYLSTON ST 9TH FLOOR BOSTON,MA02215	04-2510564	501(c)(3)	11,186	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(57) FRONTIER SCIENCE AND TECHNOLOGYP O BOX 983027 BOSTON,MA022983027	16-1056814	501(c)(3)	124,565	N/A	N/A	HVTN LABORATORY PROGRAM
(58) FRONTIER SCIENCE AND TECHNOLOGYP O BOX 983027 BOSTON,MA022983027	16-1056814	501(c)(3)	48,960	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HVTN
(59) FRONTIER SCIENCE AND TECHNOLOGYP O BOX 983027 BOSTON,MA022983027	16-1056814	501(c)(3)	92,708	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HIV PR
(60) FRONTIER SCIENCE AND TECHNOLOGYP O BOX 983027 BOSTON,MA022983027	16-1056814	501(c)(3)	35,874	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- MICRO
(61) GENERAL HOSPITAL CORPORATION DBA RESEARCH FINANCEP O BOX 414876 BOSTON,MA022414876	04-2697983	501(c)(3)	19,780	N/A	N/A	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS F
(62) GENERAL HOSPITAL CORPORATION DBA RESEARCH FINANCEP O BOX 3829 BANK OF AMERICA NA BOSTON,MA022413829	04-2697983	501(c)(3)	393,163	N/A	N/A	EXPANSION OF CARDIAC AND HEMATOPOIETIC PREGENITORS BY WN
(63) GENERAL HOSPITAL CORPORATION DBA RESEARCH FINANCEP O BOX 3829 BANK OF AMERICA NA BOSTON,MA022413829	04-2697983	501(c)(3)	43,074	N/A	N/A	MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS IN C
(64) GROUP HEALTH COOPERATIVEP O BOX 34587 SEATTLE,WA981249990	91-0511770	501(c)(3)	12,528	N/A	N/A	COLON CANCER PATHWAYS- HYPERPLASTICS POLYPS AND ADENOMA
(65) GROUP HEALTH COOPERATIVEP O BOX 34587 SEATTLE,WA981249990	91-0511770	501(c)(3)	6,733	N/A	N/A	MODELING US PROSTATE CANCER TRENDS- PSA/ TREATMENT & RAC
(66) GROUP HEALTH COOPERATIVE ATTN CASH DESKP O BOX 34587 SEATTLE,WA981249990	91-0511770	501(c)(3)	28,515	N/A	N/A	PREVENTION OF OVARIAN CANCER IN WOMEN PARTICIPATING IN M
(67) GROUP HEALTH COOPERATIVEP O BOX 34587 SEATTLE,WA981249990	91-0511770	501(c)(3)	143,185	N/A	N/A	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS F
(68) GROUP HEALTH COOPERATIVEP O BOX 34587 SEATTLE,WA981249990	91-0511770	501(c)(3)	159,961	N/A	N/A	ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATI
(69) H LEE MOFFITT CANCER CENTER MRC-RESADIM122902 MAGNOLIA DRIVE TAMPA,FL33612	59-3238634	501(c)(3)	34,612	N/A	N/A	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD
(70) H LEE MOFFITT CANCER CENTER MRC-RESADIM122902 MAGNOLIA DRIVE TAMPA,FL33612	59-3238634	501(c)(3)	55,205	N/A	N/A	IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC
(71) HARBORVIEW MEDICAL CENTER325 NINTH AVE BOX 359750 SEATTLE,WA98104	91-1631806	County Med Ctr	39,448	N/A	N/A	LIVESTRONG SURVIVORSHIP CENTER OF EXCELLENCE
(72) HEKTOEN INSTITUTE FOR MED RESEARCH LLC2240 W OGDEN AVE CHICAGO,IL606129982	36-2244897	501(c)(3)	103,957	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HIV PR
(73) HEMATOLOGICS INCP O BOX 24712 SEATTLE,WA98124	91-1685196		56,100	N/A	N/A	BRIDGE FUNDING- MOLECULAR ASSESSMENT OF MINIMAL RISK DIS
(74) HENRY M JACKSON FOUNDATION FOR THE1401 ROCKVILLE PIKE SUITE 600 ROCKVILLE,MD20852	52-1317896	501(c)(3)	210,196	N/A	N/A	HVTN LABORATORY PROGRAM
(75) IMMUNE DESIGN CORP1124 COLUMBIA ST SUITE 700 SEATTLE,WA98104	26-2007174		16,668	N/A	N/A	WASHINGTON VACCINE ALLIANCE
(76) INDIANA UNIVERSITY FINANCIAL MANAGEMENT SUPPORTP O BOX 66057 INDIANAPOLIS,IN462666057	35-6001673	University	265,622	N/A	N/A	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS F
(77) INFECTIOUS DISEASE CNSLTNTS MD PA DBA1701 N MILLS AVE ORLANDO,FL32803	59-1634257		902,898	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(78) INSTITUTE FOR SYSTEMS BIOLOGY1441 NORTH 34TH STREET SEATTLE,WA981038904	91-2003593	501(c)(3)	750,341	N/A	N/A	HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OF
(79) JOHNS HOPKINS UNIVERSITY C/O BANK OF AMERICA12529 COLLECTIONS CENTER DRIVE CHICAGO,IL60693	52-0595110	501(c)(3)	110,838	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(80) JOHNS HOPKINS UNIVERSITY C/O BANK OF AMERICA12529 COLLECTIONS CENTER DRIVE CHICAGO,IL60693	52-0595110	501(c)(3)	109,846	N/A	N/A	BIOCONDUCTOR- AN OPEN COMPUTING RESOURCE FOR GENOMICS
(81) JOHNS HOPKINS UNIVERSITY C/O BANK OF AMERICA12529 COLLECTIONS CENTER DRIVE CHICAGO,IL60693	52-0595110	501(c)(3)	12,861	N/A	N/A	GENETIC PROGRESSION OF PANCREATIC MUCINOUS CYSTIC NEOPLA
(82) KAISER FOUNDATION HOSPITALS KAISER FOUNDATION RESEARCH INSTITUTE1800 HARRISON STREET 16TH FLOOR OAKLAND,CA946123433	94-1105628	501(c)(3)	143,728	N/A	N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT
(83) KAISER FOUNDATION HOSPITALS KAISER FOUNDATION RESEARCH INSTITUTE1800 HARRISON STREET 16TH FLOOR OAKLAND,CA946123433	94-1105628	501(c)(3)	156,657	N/A	N/A	CORE ASSAYS MRLI - W1 W3
(84) KAISER FOUNDATION HOSPITALS KAISER FOUNDATION RESEARCH INSTITUTE1800 HARRISON STREET 16TH FLOOR OAKLAND,CA946123433	94-1105628	501(c)(3)	206,642	N/A	N/A	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS F
(85) KAISER FOUNDATION HOSPITALS KAISER FOUNDATION RESEARCH INSTITUTE1800 HARRISON STREET 16TH FLOOR OAKLAND,CA946123433	94-1105628	501(c)(3)	62,181	N/A	N/A	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI
(86) KAISER FOUNDATION HOSPITALS KAISER FOUNDATION RESEARCH INSTITUTE1800 HARRISON STREET 16TH FLOOR OAKLAND,CA946123433	94-1105628	501(c)(3)	17,459	N/A	N/A	UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES I
(87) LABKEY CORPORATION2226 EASTLAKE AVE E Suite 101 SEATTLE,WA98102	20-8266728	501(c)(3)	60,265	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HVTN
(88) LABKEY CORPORATION2226 EASTLAKE AVE E Suite 101 SEATTLE,WA98102	20-8266728	501(c)(3)	10,136	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- MICRO
(89) LABKEY CORPORATION2226 EASTLAKE AVE E Suite 101 SEATTLE,WA98102	20-8266728	501(c)(3)	136,078	N/A	N/A	CROSS-SPECIES HIV IMMUNOLOGY STATISTICS AND DATA CENTER
(90) LABKEY CORPORATION2226 EASTLAKE AVE E Suite 101 SEATTLE,WA98102	20-8266728	501(c)(3)	21,314	N/A	N/A	CABIG-ISRCE- IN SILICO RESEARCH CENTERS OF EXCELLENCE
(91) LOUISIANA STATE UNIVERSITY HEALTH INTERLIBRARY LOAN433 BOLIVAR ST NEW ORLEANS,LA701122223	72-6087770		36,136	N/A	N/A	IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND
(92) MAGEE WOMEN'S RESEARCH INSTITUTE OFFICE OF RESEARCH ADMINISTRATION3339 WARD STREET PITTSBURGH,PA15213	25-1462312	501(c)(3)	7,514	N/A	N/A	HVTN LABORATORY PROGRAM
(93) MASSACHUSETTS INSTITUTE OF TECHNOLOGY CASHIER'S OFFICE77 MASSACHUSETTS AVENUE NE49-3077 CAMBRIDGE,MA02139	04-2103594	501(c)(3)	60,636	N/A	N/A	HVTN LABORATORY PROGRAM
(94) MAYO CLINIC ROCHESTER DBA REMIT PROCESSINGP O BOX 4008 ROCHESTER,MN559034008	41-6011702	501(c)(3)	121,798	N/A	N/A	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI
(95) MEDICAL COLLEGE OF WISCONSIN INC FINANCE & ADMINISTRATION8701 WATERTOWN PLANK RD P O BOX 26509 MILWAUKEE,WI532260509	39-0806261	501(c)(3)	14,960	N/A	N/A	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD
(96) MEDICAL COLLEGE OF WISCONSIN INC FINANCE & ADMINISTRATION8701 WATERTOWN PLANK RD P O BOX 26509 MILWAUKEE,WI532260509	39-0806261	501(c)(3)	13,288	N/A	N/A	HEMATOPOPIETIC STEM CELL TRANSPLANTATION
(97) MEDICAL COLLEGE OF WISCONSIN INC DEPT OF PEDIATRICS M30188701 WATERTOWN PLANK RD MILWAUKEE,WI53226	39-0806261	501(c)(3)	24,722	N/A	N/A	HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION
(98) MEDICAL UNIVERSITY OF SOUTH CAROLINA CASHIERS OFFICE19 HAGOOD AVE SUITE 303 MSC 804 CHARLESTON,SC294258040	57-6000722		85,103	N/A	N/A	RADIATION DOSE-DEPENDENT INTERVENTIONS
(99) MEDICAL UNIVERSITY OF SOUTH CAROLINA CASHIERS OFFICE19 HAGOOD AVE SUITE 303 MSC 804 CHARLESTON,SC294258040	57-6000722		65,221	N/A	N/A	HVTN LABORATORY PROGRAM
(100) MIRIAM HOSPITAL RHODE ISLAND HOSPITAL593 EDDY STREET RES ADMIN-ALDRICH 3 PROVIDENCE,RI02903	05-0258905	501(c)(3)	28,080	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(101) MOUNT SINAI SCHOOL OF MEDICINEONE GUSTAVE L LEVY PLACE BOX 1410 NEW YORK,NY100296574	13-6171197	501(c)(3)	11,631	N/A	N/A	A POOLED ANALYSIS OF RISK FACTORS OF SMALL INTESTINE CAN
(102) NATIONAL INSTITUTES OF HEALTH OFM DEFS GRANT ACCOUNTING BRANCH31 CENTER DRIVE ROOM B1B11 MSC 2052 BETHESDA,MD208922052	52-0858115	NATIONAL INSTITUTES	125,000	N/A	N/A	HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OF
(103) NATIONAL JEWISH HEALTH1400 JACKSON STREET ROOM M213 DENVER,CO80206	74-2044647	501(c)(3)	6,803	N/A	N/A	A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L
(104) NEW YORK BLOOD CENTER INC1200 PROSPECT AVENUE WESTBURY,NY11590	13-1949477	501(c)(3)	985,166	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(105) NEW YORK UNIVERSITY SCHOOL OF MEDICINE ANTHONY MARSICANO-SPONSORED PROGRAMSP O BOX 415026 BOSTON,MA022415026	13-5562309		108,598	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(106) NEW YORK UNIVERSITY SCHOOL OF MEDICINE ANTHONY MARSICANO-SPONSORED PROGRAMSP O BOX 415026 BOSTON,MA022415026	13-5562309		178,833	N/A	N/A	HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OF
(107) NORTHEASTERN UNIVERSITY360 HUNTINGTON AVE BOSTON,MA02115	04-1679980	501(c)(3)	45,828	N/A	N/A	NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGIN
(108) NORTHWEST COMMUNITIES EDUCATION CENTER KDNA RADIO STATIONP O BOX 800 GRANGER,WA98932	91-0969818	501(c)(3)	26,073	N/A	N/A	PARTNERSHIP FOR A HISPANIC DIABETES PREVENTION PROGRAM
(109) NORTHWEST PORTLAND AREA INDIAN2121 SW BROADWAY STE 300 PORTLAND,OR97201	93-0718154	501(c)(3)	6,595	N/A	N/A	A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMON
(110) NY CITY DEPT OF HLTH AND MENTAL HYGIENE ROSSANA VOLPE42-09 28TH STREET WS 21-127 LONG ISLAND CITY,NY11101	13-6400434	501(c)(3)	757,632	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HIV PR
(111) OHIO STATE UNIVERSITY RSRCH FOUNDATION ACCOUNTING DEPT1960 KENNY RD 4TH FLOOR COLUMBUS,OH432101063	31-6401599	501(c)(3)	19,676	N/A	N/A	EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS IN THE
(112) OHIO STATE UNIVERSITY RSRCH FOUNDATION ACCOUNTING DEPT1960 KENNY RD 4TH FLOOR COLUMBUS,OH432101063	31-6401599	501(c)(3)	16,661	N/A	N/A	GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES
(113) OREGON HEALTH & SCIENCE UNIVERSITY SPONSORED PROJECTS ADMINISTRATION2525 SW FIRST AVENUE SUITE 220 PORTLAND,OR97201	93-1176109	University	1,425,170	N/A	N/A	HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OF
(114) OREGON HEALTH & SCIENCE UNIVERSITY SPONSORED PROJECTS ADMINISTRATION2525 SW FIRST AVENUE SUITE 220 PORTLAND,OR97201	93-1176109	University	1,371,527	N/A	N/A	IMMUNE CORRELATES OF PROTECTION AGAINST HIV AND SIV INFE
(115) OREGON HEALTH & SCIENCE UNIVERSITY3181 SW SAM JACKSON PARK ROAD PORTLAND,OR97239	93-1176109	University	15,400	N/A	N/A	THE PACIFIC NORTHWEST PROSTATE CANCER SPORE
(116) OREGON HEALTH & SCIENCE UNIVERSITY SPONSORED PROJECTS ADMINSTRATION0690 SW BANCROFT ST MAILCODE L106SPA PORTLAND,OR97239	93-1176109	University	513,586	N/A	N/A	IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND
(117) OREGON UNIVERSITY SYSTEM OFFICE OF RESEARCH SERVICES AND ADMINISTRATION5219 UNIVERSITY OF OREGON EUGENE,OR974035219	93-6001786	University	497,587	N/A	N/A	TILLING THE ZEBRAFISH GENOME- A REVERSE GENETICS APPROAC
(118) PRESIDENT AND FELLOWS OF HARVARD COLLEGEP O BOX 415649 BOSTON,MA022415649	04-2103580	501(c)(3)	129,491	N/A	N/A	GENOME-WIDE PROFILING OF HISTONE VARIANTS IN DROSOPHILA
(119) PRESIDENT AND FELLOWS OF HARVARD COLLEGEP O BOX 415649 BOSTON,MA022415649	04-2103580	501(c)(3)	24,073	N/A	N/A	STATISTICAL METHODS FOR PROSPECTIVE EVALUATION OF BIOMAR
(120) PRESIDENT AND FELLOWS OF HARVARD COLLEGEP O BOX 415649 BOSTON,MA022415649	04-2103580	501(c)(3)	8,132	N/A	N/A	GENOME-WIDE PROFILINGOF HISTONE VARIANTS IN DROSOPHILA A
(121) PRESIDENT AND FELLOWS OF HARVARD COLLEGEP O BOX 415649 BOSTON,MA022415649	04-2103580	501(c)(3)	26,182	N/A	N/A	EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAM
(122) PROVIDENCE HEALTH & SERVICES-WASHINGTON3200 PROVIDENCE DRIVE ANCHORAGE,AK99508	92-0016429	Hospital	41,114	N/A	N/A	LIVESTRONG SURVIVORSHIP CENTER OF EXCELLENCE
(123) PUBLIC HEALTH FOUNDATION ENTERPRISES INC12801 CROSSROADS PARKWAY SOUTH Suite 200 CITY OF INDUSTRY,CA91746	95-2557063	501(c)(3)	1,050,110	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(124) PUBLIC HEALTH FOUNDATION ENTERPRISES INC12801 CROSSROADS PARKWAY SOUTH Suite 200 CITY OF INDUSTRY,CA91746	95-2557063	501(c)(3)	45,693	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(125) PUGET SOUND BLOOD CENTER AND PROGRAM921 TERRY AVENUE SEATTLE,WA981041256	91-1019655	501(c)(3)	171,210	N/A	N/A	THERAPIES FOR HEMATOPOIETIC SYNDROME, BONE MARROW STROMA
(126) PUGET SOUND BLOOD CENTER AND PROGRAM921 TERRY AVENUE SEATTLE,WA981041256	91-1019655	501(c)(3)	44,763	N/A	N/A	CORE CENTER OF EXCELLENCE IN HEMATOLOGY
(127) REGENTS OF THE UNIV OF CALIFORNIA ACCOUNTING OFFICE - EMFBOX 0897 SAN FRANCISCO,CA94143	94-6036493	University	76,274	N/A	N/A	MECHANISM-BASED CLASSIFICATION AND TARGETING OF CASTRATI
(128) REGENTS OF THE UNIV OF CALIFORNIA ACCOUNTING OFFICE - EMFBOX 0897 SAN FRANCISCO,CA94143	94-6036493	University	7,905	N/A	N/A	MODELING PROSTATE CANCER CONTROL- PREVENTION/ SCREENING
(129) REGENTS OF THE UNIVERSITY BIOLOGICAL SCIENCES IIIACCOUNTING OFFICE SUITE 1400 IRVINE,CA926971050	95-2226406	University	65,036	N/A	N/A	EARLY AND REINFECTION IN HIGH RISK WOMEN
(130) REGENTS OF THE UNIVERSITY OF CA AT LOS REMITTANCE CENTER405 HILGARD AVENUE 1125 MURPHY HALL BOX 951432 LOS ANGELES,CA900959000	95-6006143	University	78,658	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(131) REGENTS OF THE UNIVERSITY OF CA AT LOS REMITTANCE CENTER405 HILGARD AVENUE 1125 MURPHY HALL BOX 951432 LOS ANGELES,CA900959000	95-6006143	University	37,945	N/A	N/A	EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CA
(132) REGENTS OF THE UNIVERSITY OF CA AT LOS REMITTANCE CENTER405 HILGARD AVENUE 1125 MURPHY HALL BOX 951432 LOS ANGELES,CA900959000	95-6006143	University	148,363	N/A	N/A	MARKERS OF B-CELL STIMULATION AS POTENTIAL PREDICTORS OF
(133) REGENTS OF THE UNIVERSITY OF CA AT LOS REMITTANCE CENTER405 HILGARD AVENUE 1125 MURPHY HALL BOX 951432 LOS ANGELES,CA900959000	95-6006143	University	22,227	N/A	N/A	GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES
(134) REGENTS OF THE UNIVERSITY OF CALIFORNIA CASHIER'S OFFICEP O BOX 989062 WEST SACRAMENTO,CA957989062	94-6036494	University	92,237	N/A	N/A	A PROSPECTIVE STUDY OF COLORECTAL CANCER- ONE-CARBON ME
(135) REGENTS OF THE UNIVERSITY OF CALIFORNIA CASHIER'S OFFICEP O BOX 989062 WEST SACRAMENTO,CA957989062	94-6036494	University	38,813	N/A	N/A	STATISTICAL METHODS FOR INTEGRATIVE ANALYSIS OF GENOMICS
(136) REGENTS OF THE UNIVERSITY OF CALIFORNIA CASHIER'S OFFICEP O BOX 989062 WEST SACRAMENTO,CA957989062	94-6036494	University	172,411	N/A	N/A	BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT
(137) REGENTS OF THE UNIVERSITY OF MICHIGANBOX 223131 PITTSBURGH,PA152512131	38-6006309	University	201,571	N/A	N/A	MODELING PROSTATE CANCER CONTROL- PREVENTION/ SCREENING
(138) REGENTS OF THE UNIVERSITY OF MINNESOTAP O BOX 1450 NW 5957 MINNEAPOLIS,MN554855957	41-6007513	University	123,125	N/A	N/A	CORE ASSAYS MRLI - W1 W3
(139) REGENTS OF THE UNIVERSITY OF MINNESOTAP O BOX 1450 NW 5957 MINNEAPOLIS,MN554855957	41-6007513	University	87,590	N/A	N/A	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS F
(140) REGENTS OF THE UNIVERSITY OF MINNESOTAP O BOX 1450 NW 5957 MINNEAPOLIS,MN554855957	41-6007513	University	9,418	N/A	N/A	IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC
(141) REGENTS OF THE UNIVERSITY OF MINNESOTAP O BOX 1450 NW 5957 MINNEAPOLIS,MN554855957	41-6007513	University	25,169	N/A	N/A	INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF
(142) REGENTS OF THE UNIVERSITY OF MINNESOTAP O BOX 1450 NW 5957 MINNEAPOLIS,MN554855957	41-6007513	University	51,499	N/A	N/A	METABOLIC SYNDROME FOLLOWING TRANSPLANT FOR LEUKEMIA
(143) REGENTS OF UNIVERSITY OF COLORADO OFFICE OF GRANTS & CONTRACTS-F428DEPARTMENT 238 DENVER,CO802910238	84-6000555	University	186,819	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(144) REGENTS OF UNIVERSITY OF COLORADO OFFICE OF GRANTS & CONTRACTS-F428DEPARTMENT 238 DENVER,CO802910238	84-6000555	University	45,639	N/A	N/A	VITAMIN D AND PROSTATE CANCER- BIOMARKERS AND GENETIC VA
(145) RESEARCH FOUNDATION OF STATE UNIVERSITY CASH RECEIPT DEPARTMENTP O BOX 9 ALBANY,NY122010009	14-1368361	501(c)(3)	63,436	N/A	N/A	POPULATION PHARMACOKINETICS / PHARMACODYNAMICS IN NONABL
(146) RUSH UNIVERSITY MEDICAL CENTER FUND ACCOUNTING1700 WEST VAN BUREN ROOM 277 CHICAGO,IL60612	36-2174823	501(c)(3)	12,945	N/A	N/A	PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM
(147) SAINT JUDE CHILDRENS RESEARCH HOSPITALP O BOX 1000 DEPT 949 MEMPHIS,TN381480949	62-0646012	501(c)(3)	18,899	N/A	N/A	LATE EFFECTS OF TREATMENT IN WILMS-TUMOR SURVIVORS AND O
(148) SAINT LOUIS UNIVERSITY3700 WEST PINE MALL FUSZ MEMORIAL HALL SUITE 357 SAINT LOUIS,MO63108	43-0654872	501(c)(3)	12,794	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(149) SEATTLE BIOMEDICAL RESEARCH INSTITUTE307 WESTLAKE AVE N SUITE 500 SEATTLE,WA981095219	91-0961784	501(c)(3)	179,138	N/A	N/A	IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND
(150) SEATTLE CHILDREN'SP O BOX 34935 DEPT 736 SEATTLE,WA981241936	91-0564748	501(c)(3)	7,369	N/A	N/A	LIVESTRONG SURVIVORSHIP CENTER OF EXCELLENCE
(151) SEATTLE CHILDREN'SP O BOX 34935 DEPT 736 SEATTLE,WA981241936	91-0564748	501(c)(3)	90,319	N/A	N/A	STEM CELL TRANSPLANTATION- BASIC/CLINICAL RESEARCH
(152) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	97,885	N/A	N/A	FUNCTION OF HUMAN AND MOUSE BETA-GLOBIN LOCUS CONTROL RE
(153) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	27,690	N/A	N/A	PREGNANCY, MICROCHIMERISM, AND AUTOIMMUNE DISEASE
(154) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	143,530	N/A	N/A	CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)
(155) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	50,890	N/A	N/A	ACTIVATION AND SILENCING OF GENE EXPRESSION DURING HEMAT
(156) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	87,919	N/A	N/A	TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMOR
(157) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	33,020	N/A	N/A	TOWARDS A MODEL OF FANCONI ANEMIA
(158) SEATTLE CHILDREN'SP O BOX 34935 DEPT 736 SEATTLE,WA981241936	91-0564748	501(c)(3)	21,330	N/A	N/A	DIGITAL DNASEL MAPPING AND FOOTPRINTING OF THE MOUSE GEN
(159) SEATTLE CHILDREN'SP O BOX 34935 DEPT 736 SEATTLE,WA981241936	91-0564748	501(c)(3)	115,368	N/A	N/A	METABOLIC SYNDROME FOLLOWING TRANSPLANT FOR LEUKEMIA
(160) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	31,899	N/A	N/A	CONSORTIUM BIOSPECIMEN PROGRAM
(161) SEATTLE CHILDREN'SP O BOX 24728 SEATTLE,WA981240728	91-0564748	501(c)(3)	21,255	N/A	N/A	A COMPREHENSIVE CATALOGUE OF MOUSE DNASEI HYPERSENSITIVE
(162) SEATTLE INST FOR BIOMED & CLINICAL RES1660 SOUTH COLUMBIAN WAY S-151F SEATTLE,WA98108	91-1452438	501(c)(3)	207,761	N/A	N/A	THE PACIFIC NORTHWEST PROSTATE CANCER SPORE
(163) SEATTLE INST FOR BIOMED & CLINICAL RES1660 SOUTH COLUMBIAN WAY S-151F SEATTLE,WA98108	91-1452438	501(c)(3)	36,970	N/A	N/A	IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMA
(164) SLOAN KETTERING INSTITUTE FOR MSKCC FINANCEP O BOX 26338 GENERAL POST OFFICE NEW YORK,NY10087	13-1624182	501(c)(3)	26,131	N/A	N/A	GENOME-WIDE ASSOCIATION STUDY OF ENDOMETRIAL CANCER
(165) SLOAN KETTERING INSTITUTE FOR MSKCC FINANCEP O BOX 26338 GENERAL POST OFFICE NEW YORK,NY10087	13-1624182	501(c)(3)	63,504	N/A	N/A	HEMATOPOPIETIC STEM CELL TRANSPLANTATION
(166) SLOAN KETTERING INSTITUTE FOR MSKCC FINANCEP O BOX 26338 GENERAL POST OFFICE NEW YORK,NY10087	13-1624182	501(c)(3)	229,160	N/A	N/A	HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION
(167) SUNNYSIDE COMMUNITY HOSPITAL INCP O BOX 719 SUNNYSIDE,WA98944	91-1286274	501(c)(3)	56,658	N/A	N/A	PARTNERSHIP FOR A HISPANIC DIABETES PREVENTION PROGRAM
(168) SWEDISH HEALTH SERVICES SWEDISH HEALTH SERVICES GRANTSP O BOX 94085 SEATTLE,WA981249485	91-0433740	501(c)(3)	10,765	N/A	N/A	PREVENTION OF OVARIAN CANCER IN WOMEN PARTICIPATING IN M
(169) TORREY PINES INST FOR MOLECULAR STUDIES11350 SW VILLAGE PARKWAY PORT ST LUCIE,FL34987	33-0319501	501(c)(3)	165,937	N/A	N/A	IDENTIFICATION OF T CELL-DEFINED ANTIGENS IN OVARIAN CAN
(170) TRANSLATIONAL GENOMICS RES INSTITUTE445 N 5TH ST SUITE 600 PHOENIX,AZ85004	75-3065445	501(c)(3)	26,253	N/A	N/A	GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS IN C
(171) TRANSLATIONAL GENOMICS RES INSTITUTE445 N 5TH ST SUITE 600 PHOENIX,AZ85004	75-3065445	501(c)(3)	55,174	N/A	N/A	A PROSPECTIVE STUDY OF COLORECTAL CANCER- ONE-CARBON ME
(172) TRANSLATIONAL GENOMICS RES INSTITUTE445 N 5TH ST SUITE 600 PHOENIX,AZ85004	75-3065445	501(c)(3)	90,306	N/A	N/A	EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS IN THE
(173) TRANSLATIONAL GENOMICS RES INSTITUTE445 N 5TH ST SUITE 600 PHOENIX,AZ85004	75-3065445	501(c)(3)	716,287	N/A	N/A	INFLAMMATION AND THROMBOSIS GENE PATHWAYS AND CARDIOVASC
(174) TRANSLATIONAL GENOMICS RES INSTITUTE445 N 5TH ST SUITE 600 PHOENIX,AZ85004	75-3065445	501(c)(3)	360,551	N/A	N/A	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR
(175) TRANSLATIONAL GENOMICS RES INSTITUTE445 N 5TH ST SUITE 600 PHOENIX,AZ85004	75-3065445	501(c)(3)	162,204	N/A	N/A	EPIDEMIOLOGY OF PUTATIVE GENUINE GENETIC VARIANT- THE WO
(176) TRUSTEES OF COLUMBIA UNIVERSITY IN CU RESEARCH ADMINISTRATIONP O BOX 29789 NEW YORK,NY100879789	13-5598093	501(c)(3)	1,592,938	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(177) TRUSTEES OF THE UNIVERSITY OFP O BOX 785541 PHILADELPHIA,PA191785541	23-1352685	501(c)(3)	18,023	N/A	N/A	TREC COORDINATION CENTER
(178) TRUSTEES OF THE UNIVERSITY OFP O BOX 785541 PHILADELPHIA,PA191785541	23-1352685	501(c)(3)	1,462,383	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(179) TRUSTEES OF THE UNIVERSITY OFP O BOX 785541 PHILADELPHIA,PA191785541	23-1352685	501(c)(3)	53,057	N/A	N/A	GENOME-WIDE ASSOCIATION STUDY OF ENDOMETRIAL CANCER
(180) UNIVERSITY OF ALABAMA BIRMINGHAM GRANTS AND CONTRACTS ACCOUNTING1530 THIRD AVENUE SOUTH AB 990 BIRMINGHAM,AL352940109	63-6005396	University	583,202	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(181) UNIVERSITY OF GEORGIA RESEARCH UGA CONTRACTS & GRANTS C/O PAM RAY475 N LUMPKIN STREET Athens,GA30602	58-1353149	501(c)(3)	5,168	N/A	N/A	FUNCTIONAL METHODS FOR RADIATION EXPOSURE AND BIOMARKER
(182) UNIVERSITY OF HAWAII OFFICE OF RESEARCH SERVICES2530 DOLE STREET SAKAMAKI D200 HONOLULU,HI96822	99-6000354	University	117,148	N/A	N/A	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR
(183) UNIVERSITY OF IDAHO OFFICE OF SPONSORED PROGRAMSP O BOX 443020 MOSCOW,ID838443020	82-6000945	University	7,090	N/A	N/A	WASHINGTON VACCINE ALLIANCE
(184) UNIVERSITY OF IDAHO OFFICE OF SPONSORED PROGRAMSP O BOX 443020 MOSCOW,ID838443020	82-6000945	University	113,425	N/A	N/A	WASHINGTON VACCINE ALLIANCE
(185) UNIVERSITY OF NEW MEXICO HSC CONTRACT AND GRANT ACCOUNTING1 UNIVERSITY OF NEW MEXICO MSC09 5225 ALBUQUERQUE,NM871310001	85-6000642	University	51,671	N/A	N/A	REDUCING OBESITY AT THE WORKPLACE- A RANDOMIZED TRIAL
(186) UNIVERSITY OF NEW MEXICO HSC CONTRACT AND GRANT ACCOUNTING1 UNIVERSITY OF NEW MEXICO MSC09 5225 ALBUQUERQUE,NM871310001	85-6000642	University	39,700	N/A	N/A	TREC- MECHANISMS OF ENERGY BALANCE AND CANCER PREVENTION
(187) UNIVERSITY OF NEW MEXICO HSC CONTRACT AND GRANT ACCOUNTING1 UNIVERSITY OF NEW MEXICO MSC09 5225 ALBUQUERQUE,NM871310001	85-6000642	University	79,375	N/A	N/A	TREC COORDINATION CENTER
(188) UNIVERSITY OF NEW MEXICO HSC CONTRACT AND GRANT ACCOUNTING1 UNIVERSITY OF NEW MEXICO MSC09 5225 ALBUQUERQUE,NM871310001	85-6000642	University	283,549	N/A	N/A	UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES I
(189) UNIVERSITY OF NO CAROLINA AT CHARLOTTE FINANCIAL SERVICES/SPONSORED PROGRAMS9201 UNIVERSITY CITY BOULEVARD CHARLOTTE,NC282230001	56-0791228	University	98,266	N/A	N/A	STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS
(190) UNIVERSITY OF NORTH CAROLINA OFFICE OF SPONSORED RESEARCHP O BOX 402420 ATLANTA,GA303842420	56-6001393	University	244,549	N/A	N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT
(191) UNIVERSITY OF NORTH CAROLINA OFFICE OF SPONSORED RESEARCHP O BOX 402420 ATLANTA,GA303842420	56-6001393	University	23,315	N/A	N/A	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI
(192) UNIVERSITY OF NORTH CAROLINA OFFICE OF SPONSORED RESEARCHP O BOX 402420 ATLANTA,GA303842420	56-6001393	University	26,613	N/A	N/A	MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS IN C
(193) UNIVERSITY OF NORTH CAROLINA OFFICE OF SPONSORED RESEARCHP O BOX 402420 ATLANTA,GA303842420	56-6001393	University	51,675	N/A	N/A	STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS
(194) UNIVERSITY OF PITTSBURGH OFFICE OF RES/COST ACCTG3109 CATHEDRAL OF LEARNING PITTSBURGH,PA15260	25-0965591	501(c)(3)	15,359	N/A	N/A	HVTN LABORATORY PROGRAM
(195) UNIVERSITY OF PITTSBURGHP O BOX 371220 PITTSBURGH,PA152517220	25-0965591	501(c)(3)	17,928	N/A	N/A	EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS IN THE
(196) UNIVERSITY OF PITTSBURGH OFFICE OF RES/COST ACCTG3109 CATHEDRAL OF LEARNING PITTSBURGH,PA15260	25-0965591	501(c)(3)	24,793	N/A	N/A	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR
(197) UNIVERSITY OF PITTSBURGH OFFICE OF RES/COST ACCTG3109 CATHEDRAL OF LEARNING PITTSBURGH,PA15260	25-0965591	501(c)(3)	16,424	N/A	N/A	GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES
(198) UNIVERSITY OF PITTSBURGH642 B SCAIFE HALL 3550 TERRACE STREET PITTSBURGH,PA15261	25-0965591	501(c)(3)	15,150	N/A	N/A	A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L
(199) UNIVERSITY OF ROCHESTER OFFICE OF RESEARCH ACCT & COST STANDARDS910 GENESEE STREET SUITE 200 ROCHESTER,NY146113847	16-0743209		1,160,817	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(200) UNIVERSITY OF ROCHESTER OFFICE OF RESEARCH ACCT & COST STANDARDS910 GENESEE STREET SUITE 200 ROCHESTER,NY146113847	16-0743209		181,772	N/A	N/A	THE PATHOGENESIS OF FMD- FACIOSCAPULOHUMERAL MUSCULAR
(201) UNIVERSITY OF SOUTHERN CALIFORNIA FILE NO 52095SPONSORED PROJECTS ACCOUNTING LOS ANGELES,CA900742095	95-1642394		17,198	N/A	N/A	BIOLOGY AND PROGNOSTIC IMPLICATIONS OF FLT3 MUTATIONS IN
(202) UNIVERSITY OF SOUTHERN CALIFORNIA FILE NO 52095SPONSORED PROJECTS ACCOUNTING LOS ANGELES,CA900742095	95-1642394		20,599	N/A	N/A	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI
(203) UNIVERSITY OF SOUTHERN CALIFORNIA FILE NO 52095SPONSORED PROJECTS ACCOUNTING LOS ANGELES,CA900742095	95-1642394		207,595	N/A	N/A	IMPROVING EARLY DETECTION OF BREAST CANCER WITH A BLOOD
(204) UNIVERSITY OF SOUTHERN CALIFORNIA FILE NO 52095SPONSORED PROJECTS ACCOUNTING LOS ANGELES,CA900742095	95-1642394		21,068	N/A	N/A	IRF8 AS A BIOMARKER OF AGING, MALIGNANT TRANSFORMATION,
(205) UNIVERSITY OF SOUTHERN CALIFORNIA FILE NO 52095SPONSORED PROJECTS ACCOUNTING LOS ANGELES,CA900742095	95-1642394		5,445	N/A	N/A	THE BREAST CANCER BIOMARKER DISCOVERY CONSORTIUM- PHASE
(206) UNIVERSITY OF SOUTHERN CALIFORNIA FILE NO 52095SPONSORED PROJECTS ACCOUNTING LOS ANGELES,CA900742095	95-1642394		70,556	N/A	N/A	BIOMARKER FOR RISK IDENTIFICATION AND RISK-BASED THERAPY
(207) UNIVERSITY OF TEXAS HEALTH SCIENCES FINANCIAL ADMINSTRATIVE SUPPORTP O BOX 203382 HOUSTON,TX772163382	74-1761309	University	34,049	N/A	N/A	PROSTAGLANDIN SYNTHESIS, GENETICS AND COLORECTAL CANCER
(208) UNIVERSITY OF TEXAS HEALTH SCIENCES FINANCIAL ADMINSTRATIVE SUPPORTP O BOX 203382 HOUSTON,TX772163382	74-1761309	University	9,671	N/A	N/A	PREGNANCY, MICROCHIMERISM, AND AUTOIMMUNE DISEASE
(209) UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL OFFICE OF POST AWARD ADMINISTRATIONP O BOX 841765 DALLAS,TX752841765	75-6002868	University	663,573	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(210) UNIVERSITY OF TEXAS MD ANDERSON GRANTS & CONTRACTS ACCOUNTINGP O BOX 4390 HOUSTON,TX772104390	74-6001118		293,764	N/A	N/A	IMPROVING EARLY DETECTION OF BREAST CANCER WITH A BLOOD
(211) UNIVERSITY OF UTAH GRANTS & CONTRACTS ACCOUNTING201 S PRESIDENTS CIRCLE RM 406 SALT LAKE CITY,UT841129020	87-6000525	University	93,134	N/A	N/A	PROSTAGLANDIN SYNTHESIS, GENETICS AND COLORECTAL CANCER
(212) UNIVERSITY OF UTAH GRANTS & CONTRACTS ACCOUNTING201 S PRESIDENTS CIRCLE RM 406 SALT LAKE CITY,UT841129020	87-6000525	University	52,618	N/A	N/A	GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS IN C
(213) UNIVERSITY OF UTAH GRANTS & CONTRACTS ACCOUNTING201 S PRESIDENTS CIRCLE RM 406 SALT LAKE CITY,UT841129020	87-6000525	University	79,474	N/A	N/A	THE TIME DISTRIBUTION METHOD FOR MEASURING CLINICALLY VA
(214) UNIVERSITY OF VERMONT ANDP O BOX 1389 WILLISTON,VT054951389	03-0179440	University	12,820	N/A	N/A	A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L
(215) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	5,224	N/A	N/A	VANGUARD CLINICAL CENTER FOR CLINICAL TRIAL & OBSERVATIO
(216) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	23,322	N/A	N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT
(217) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	33,210	N/A	N/A	ENHANCING LONG-TERM 5-A-DAY BEHAVIOR CHANGE IN WORKSITES
(218) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	170,869	N/A	N/A	REDUCING OBESITY AT THE WORKPLACE- A RANDOMIZED TRIAL
(219) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	27,032	N/A	N/A	HEPATITIS B ESL EDUCATION FOR CHINESE
(220) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	279,158	N/A	N/A	THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
(221) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	10,170	N/A	N/A	MODELING US PROSTATE CANCER TRENDS- PSA/ TREATMENT & RAC
(222) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	175,563	N/A	N/A	RADIATION DOSE-DEPENDENT INTERVENTIONS
(223) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	20,101	N/A	N/A	CORE CENTER OF EXCELLENCE IN HEMATOLOGY
(224) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	260,501	N/A	N/A	TREC- MECHANISMS OF ENERGY BALANCE AND CANCER PREVENTION
(225) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	46,849	N/A	N/A	ASTATINE-211 CONDITIONING FOR NONMYELOABLATIVE HEMOPOIET
(226) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	10,690	N/A	N/A	THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS
(227) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	5,074,474	N/A	N/A	HVTN LABORATORY PROGRAM
(228) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	53,229	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HVTN
(229) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	271,858	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- HIV PR
(230) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	167,751	N/A	N/A	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS- MICRO
(231) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	2,843,022	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(232) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	39,353	N/A	N/A	GENE THERAPY FOR FANCONI ANEMIA
(233) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	93,459	N/A	N/A	CORD BLOOD EXPANSION AND TRANSPLANTATION IN A NON-HUMAN
(234) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	52,541	N/A	N/A	HARNESSING INNATE IMMUNITY TO ENHANCE IMMUNOGENICITY OF
(235) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	105,188	N/A	N/A	IN UTERO TRANSPLANTATION IN PRIMATES
(236) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	9,903	N/A	N/A	HEMATOPOIETIC CHEMOPROTECTION IN GLIOBLASTOMA PATIENTS
(237) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	58,052	N/A	N/A	CORE ASSAYS MRLI - W1 W3
(238) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	354,034	N/A	N/A	SEATTLE VACCINE TRIALS UNIT
(239) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	124,618	N/A	N/A	LATE EFFECTS OF TREATMENT IN WILMS-TUMOR SURVIVORS AND O
(240) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	5,345	N/A	N/A	TGF-beta SIGNALING AND COLON CANCER
(241) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	296,333	N/A	N/A	CYTOTOXIC T CELL RESPONSE TO HSV IN HIV INFECTED PEOPLE
(242) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	37,946	N/A	N/A	THE FANCONI ANEMIA-BRCA PATHWAY AND CHEMOSENSITIVITY OF
(243) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	438,532	N/A	N/A	IMMUNE CORRELATES OF PROTECTION AGAINST HIV AND SIV INFE
(244) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	6,598	N/A	N/A	HPV- BIOLOGY, CLINICAL SIGNIFICANCE AND EPIDEMIOLOGY
(245) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	14,346	N/A	N/A	NIGHT SHIFT WORK AND HORMONE LEVELS IN MEN
(246) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	45,817	N/A	N/A	IMPROVING GASTROINTESTINAL RECOVERY AFTER RADIATION
(247) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	14,824	N/A	N/A	A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMON
(248) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	118,163	N/A	N/A	CHARACTERIZATION OF HIV-1 ANTIBODY RESPONSES IN CHRONICA
(249) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	269,084	N/A	N/A	IMMUNOTHERAPY OF HEMATOLOGICAL MALIGNANCIES
(250) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	747,154	N/A	N/A	THE PACIFIC NORTHWEST PROSTATE CANCER SPORE
(251) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	147,366	N/A	N/A	PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
(252) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	102,860	N/A	N/A	THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSI
(253) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	45,106	N/A	N/A	A PROSPECTIVE STUDY OF COLORECTAL CANCER- ONE-CARBON ME
(254) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	17,853	N/A	N/A	EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CA
(255) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	1,837,844	N/A	N/A	CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC H
(256) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	201,405	N/A	N/A	FRED HUTCHINSON/UNIVERSITY OF WASHINGTON CANCER CONSORTI
(257) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	28,092	N/A	N/A	OUTCOMES BASED GUIDELINE DEVELOPMENT FOR PROSTATE CANCER
(258) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	7,716	N/A	N/A	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS F
(259) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	1,954,635	N/A	N/A	CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)
(260) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	230,773	N/A	N/A	MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS
(261) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	72,753	N/A	N/A	IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMA
(262) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	69,340	N/A	N/A	CD8+ CELL IMMUNITY TO CYTOMEGALOVIRUS
(263) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	126,623	N/A	N/A	MITIGATION OF RADIATION-INDUCED LUNG INJURY IN THE DOG M
(264) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	19,193	N/A	N/A	WASHINGTON VACCINE ALLIANCE
(265) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	158,660	N/A	N/A	CD45 PRETARGETED RADIOIMMUNOTHERAPY FOR AML
(266) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	1,309,088	N/A	N/A	MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN
(267) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	26,099	N/A	N/A	NORTH AMERICAN SHWACHMAN-DIAMOND SYNDROME REGISTRY
(268) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	226,679	N/A	N/A	DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES IN THE
(269) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	8,145	N/A	N/A	SCHWACHMAN-DIAMOND SYNDROME INTERNATIONAL REGISTRY AND R
(270) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	851,622	N/A	N/A	PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM
(271) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	155,909	N/A	N/A	INNATE RESISTANCE TO MUCOSAL HSV INFECTION IN HUMANS
(272) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	47,623	N/A	N/A	ORAL CANCER- MOLECULAR PROFILES & CLINICAL OUTCOMES
(273) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	209,749	N/A	N/A	CHEMOPROTECTION AGAINST AMINOGLYCOSIDE-INDUCED OTOTOXICI
(274) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	99,879	N/A	N/A	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSOR
(275) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	293,477	N/A	N/A	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI
(276) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	57,389	N/A	N/A	PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYST
(277) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	29,947	N/A	N/A	INFLAMMATORY DENDRITIC CELLS IN ADIPOSE TISSUE INFLAMMAT
(278) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	234,061	N/A	N/A	SEATTLE CANCER CONSORTIUM BREAST SPORE
(279) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	142,177	N/A	N/A	DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIE
(280) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	72,981	N/A	N/A	HIV TESTING IN GENITAL TRACT SECRETIONS - MERCK SITES' S
(281) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	29,723	N/A	N/A	HPV CAPSID ANTIBODIES
(282) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	439,542	N/A	N/A	INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF
(283) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	48,877	N/A	N/A	ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WI
(284) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	254,771	N/A	N/A	CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO
(285) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	564,632	N/A	N/A	EXPANSION OF CARDIAC AND HEMATOPOIETIC PREGENITORS BY WN
(286) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	307,517	N/A	N/A	THE PATHOGENESIS OF FMD- FACIOSCAPULOHUMERAL MUSCULAR
(287) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	167,057	N/A	N/A	UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES I
(288) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	361,601	N/A	N/A	CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER
(289) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	88,292	N/A	N/A	ANALYZING HETEROGENEITY OF ONCOGENIC PATHWAY ACTIVATION
(290) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	14,408	N/A	N/A	MERCK AURORA KINASE A INHIBITOR STUDY (MK-5108)
(291) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	60,137	N/A	N/A	A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE L
(292) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	42,719	N/A	N/A	LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND O
(293) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	100,652	N/A	N/A	GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS IN C
(294) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	202,864	N/A	N/A	CONSORTIUM BIOSPECIMEN PROGRAM
(295) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	196,702	N/A	N/A	EARLY AND REINFECTION IN HIGH RISK WOMEN
(296) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	59,201	N/A	N/A	NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGIN
(297) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	144,659	N/A	N/A	VIRAL PANELS DATABASE
(298) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	10,744	N/A	N/A	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS
(299) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	24,900	N/A	N/A	LYMPH NODE ALTERATIONS IN CANCER
(300) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	149,868	N/A	N/A	STRATEGIES TO IMPROVE THE ADOPTIVE TRANSFER OF T CELLS
(301) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	17,110	N/A	N/A	NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)
(302) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	68,121	N/A	N/A	MODELING PROSTATE CANCER CONTROL- PREVENTION/ SCREENING
(303) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	13,412	N/A	N/A	ADIPOSE TISSUE INFLAMMATION AND ESTROGEN SYNTHESIS
(304) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	89,979	N/A	N/A	STATISTICAL METHODS IN HIV/AIDS RESEARCH
(305) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	58,352	N/A	N/A	NOVEL COMPUTATIONAL TOOLS FOR STUDYING THE HUMAN MICROBI
(306) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	156,777	N/A	N/A	CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS
(307) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	40,388	N/A	N/A	CORE CENTER OF EXCELLENCE IN HEMATOLOGY
(308) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	68,194	N/A	N/A	CORE CENTER OF EXCELLENCE IN HEMATOLOGY
(309) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	149,283	N/A	N/A	WASHINGTON VACCINE ALLIANCE
(310) UNIVERSITY OF WASHINGTON12455 COLLECTIONS DRIVE CHICAGO,IL606930001	91-6001537	University	810,196	N/A	N/A	FRED HUTCHINSON/UNIVERSITY OF WASHINGTON CANCER CONSORTI
(311) UNIVERSITY OF WISCONSIN OFFICE FOR RESEARCH and SPONSORED PROGRAMSDRAWER 538 MILWAUKEE,WI532780538	39-6006492	University	7,491	N/A	N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT
(312) UNIVERSITY OF WISCONSIN OFFICE FOR RESEARCH and SPONSORED PROGRAMSDRAWER 538 MILWAUKEE,WI532780538	39-6006492	University	68,304	N/A	N/A	NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)
(313) VACCINE & GENE THERAPY INSTITUTE FLORIDA11350 SW VILLAGE PARKWAY 3RD FLOOR PORT ST LUCIE,FL34987	36-4631835	501(c)(3)	326,756	N/A	N/A	HVTN LABORATORY PROGRAM
(314) VANDERBILT UNIVERSITY DEPT OF FINANCEDEPT AT 40303 ATLANTA,GA311920303	62-0476822	501(c)(3)	986,374	N/A	N/A	LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL
(315) VANDERBILT UNIVERSITY DEPT OF FINANCEDEPT AT 40303 ATLANTA,GA311920303	62-0476822	501(c)(3)	25,261	N/A	N/A	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD
(316) VANDERBILT UNIVERSITY2301 VANDERBILT PLACE PMB 401591 NASHVILLE,TN372401591	62-0476822	501(c)(3)	385,191	N/A	N/A	TILLING THE ZEBRAFISH GENOME- A REVERSE GENETICS APPROAC
(317) WAKE FOREST UNIVERSITY HEALTH SCIENCES CONTROLLERS OFFICEMEDICAL CENTER BOULEVARD WINSTON SALEM,NC27157	22-3849199	501(c)(3)	290,404	N/A	N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INIT
(318) WASHINGTON STATE UNIVERSITY CASHIERS OFFICEP O BOX 641039 PULLMAN,WA991641039	91-6001108	University	103,346	N/A	N/A	ENGINEERING ENZYMES FOR ANTI-TUMOR SUICIDE GENE THERAPY
(319) WASHINGTON STATE UNIVERSITY CASHIER'S OFFICE-SPSP O BOX 641027 240 FRENCH ADMINSTRATION BLDG PULLMAN,WA991641027	91-6001108	University	205,475	N/A	N/A	WASHINGTON VACCINE ALLIANCE
(320) WASHINGTON UNIVERSITY DBA SPONSORED PROJECTS ACCOUNTING700 ROSEDALE AVENUE CAMPUS BOX 1034 ST LOUIS,MO631121408	43-0653611	501(c)(3)	83,220	N/A	N/A	RADIATION DOSE-DEPENDENT INTERVENTIONS
(321) WASHINGTON UNIVERSITY DBA ATTN WESTERVELT/TMP4172/944214660 SOUTH EUCLID AVE CB8009 ST LOUIS,MO631108009	43-0653611	501(c)(3)	5,400	N/A	N/A	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD
(322) WEILL MEDICAL COLLEGE OF CORNELL UNIV RESEARCH ACCOUNTING DEPARTMENT100 BROADWAY 8TH FLOOR NEW YORK,NY10005	13-1623978		10,039	N/A	N/A	HVTN LABORATORY PROGRAM
(323) WISTAR INSTITUTE OF ANATOMY AND BIOLOGY3601 SPRUCE STREET PHILADELPHIA,PA19104	23-6434390	501(c)(3)	83,241	N/A	N/A	BARRETT'S ESOPHAGUS- PREDICTORS OF PROGRESSION
(324) YALE UNIVERSITY GRANTS & CONTRACT FINANCIAL ADMINP O BOX 1873 NEW HAVEN,CT065081873	06-0646973	501(c)(3)	15,977	N/A	N/A	TREC COORDINATION CENTER
(325) YALE UNIVERSITY GRANTS & CONTRACT FINANCIAL ADMINP O BOX 1873 NEW HAVEN,CT065081873	06-0646973	501(c)(3)	73,114	N/A	N/A	ADULT LEUKEMIA RESEARCH CENTER
(326) YALE UNIVERSITY GRANTS & CONTRACT FINANCIAL ADMINP O BOX 1873 NEW HAVEN,CT065081873	06-0646973	501(c)(3)	8,460	N/A	N/A	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTI
(327) YESHIVA UNIVERSITY ALBERT EINSTEIN COLLEGE OF MEDICINE1300 MORRIS PARK AVE BELFER BLDG RM 1108 BRONX,NY10461	13-1624225	501(c)(3)	8,709	N/A	N/A	INNATE RESISTANCE TO MUCOSAL HSV INFECTION IN HUMANS

Enter total number of section 501(c)(3) and government organizations ......................... Bullet Image

143

Enter total number of other organizations ................................ . Bullet Image

184

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2010

Page 2

Part III

Grants and Other Assistance to Individuals in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 22.
Use Schedule I-1 (Form 990) if additional space is needed.

(a)Type of grant or assistance	(b)Number of recipients	(c)Amount of cash grant	(d)Amount of non-cash assistance	(e)Method of valuation (book, FMV, appraisal, other)	(f)Description of non-cash assistance

Part IV

Supplemental Information. Complete this part to provide the information required in Part I, line 2, and any other additional information.

Identifier	Return Reference	Explanation
SchI_P01_S00_L02	Schedule I, Part I, Line 2	Schedule I, Part I, Line 2 - Procedures for Monitoring the Use of Grant Funds: Once the notice of award has been received and the Center project ID activated, the subaward can be set up. The structure of the subaward will depend on how the Prime is set up. Generally at the Center, a new purchase order (PO) is requisitioned for each subaward for each year of a project. This allows the Research Coordinator (RC) to closely monitor subaward invoices and encumbrances. For our Subrecipients, it means a separate budget ID and final invoice each year. Carryover between years is not automatic. There are 5 primary stems. 1) Step one is within Office of Sponsored Research (OSR). The Grant Specialist notifies the Contract Specialist that a grant which includes a subaward has been funded, and provides to the Contract Specialist a copy of the award, the signed subaward application (if available) and any special instructions. A signed subaward application is important because it shows that the Subrecipient organization has reviewed and approved the budget and scope of work. 2) The RC sends the Contract Specialist a Subcontract Acquisition Form (SAF). This form provides authorization for the Contract Specialist to issue the subaward, and includes a scope of work, budget, and pertinent subrecipient information. It is necessary to provide the scope of work and budget on the SAF as these items may have changed from what was originally submitted in the subaward application. 3) The Contract Specialist requisitions the subaward PO, which the RC must approve. An e-mail is sent to the RC notifying them that the requisition is pending and requires approval. Because OSR does not have funds commitment authority the RC is required to approve all requisitions. 4) OSR collects information required to correctly set up the subaward. These items include Institutional Review Office (IRO) and Institutional Animal Care and Use Committee (IACUC) approval dates, confirmation of subaward Facilities and Administrative (F&A) rates and A-133 Audit reports, review of Prime special terms and conditions to determine flow-down, confirmation that the Subrecipient is not debarred, and other similar regulatory and administrative requirements. While much of this information is collected by OSR, the RC may, in addition to completing the SAF, be asked to assist in the collection of some of the documentation. 5) OSR writes the subaward agreement, and mails it to the Subrecipient for signature. Some agreements can be signed by OSR before mailing, while others will be sent unsigned. This is determined by the Contract Specialist based on the term of award and status of administrative and regulatory requirements. A copy of the initial subaward is sent to the RC. Once the subaward has been fully signed, a copy is sent to the RC for their files. No invoices should be approved by the RC until they have received a fully executed agreement.

Schedule I (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" to Form 990,
Part IV, question 23.
SchJMediumBullet

Attach to Form 990. SchJMediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed in Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement orprovision of all the expenses described above? If "No," complete Part III to explain....

Yes

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
officers, directors, trustees, and the CEO/Executive Director, regarding the items checked in line 1a? ....

Yes

Indicate which, if any, of the following the organization uses to establish the compensation of the
organization's CEO/Executive Director. Check all that apply.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? ...............

Participate in, or receive payment from, a supplemental nonqualified retirement plan? ........

Participate in, or receive payment from, an equity-based compensation arrangement? ........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9.

For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 5a or 5b, describe in Part III.

For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 6a or 6b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported in Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regs. section 53.4958-4(a)(3)? If "Yes," describe
in Part III .............................

If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Privacy Act and Paperwork Reduction Act Notice, see the Intructions for Form 990

Cat. No. 50053T

Schedule J (Form 990) 2010

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use Schedule J-1 if additional space needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.

Note. The sum of columns (B)(i)-(iii) must equal the applicable column (D) or column (E) amounts on Form 990, Part VII, line 1a.

(A) Name		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported in prior Form 990 or Form 990-EZ
(A) Name		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
(1) Leland H Hartwell	(i) (ii)	468,409 0	124,481 0	0 0	0 0	41,293 0	634,183 0	0 0
(2) Frederick R Appelbaum	(i) (ii)	519,933 0	68,421 0	0 0	0 0	43,686 0	632,040 0	0 0
(3) Janell E Baldwin	(i) (ii)	182,337 0	20,000 0	0 0	0 0	32,522 0	234,859 0	0 0
(4) Anthony Bozzuti	(i) (ii)	243,506 0	12,250 0	0 0	0 0	16,074 0	271,830 0	0 0
(5) Jonathan Cooper	(i) (ii)	262,763 0	0 0	0 0	0 0	38,439 0	301,202 0	0 0
(6) Linda L Gainer	(i) (ii)	216,720 0	30,000 0	0 0	0 0	43,292 0	290,012 0	0 0
(7) Mark T Groudine	(i) (ii)	319,280 0	148,900 0	0 0	16,500 0	44,556 0	529,236 0	0 0
(8) Randall C Main	(i) (ii)	328,324 0	40,000 0	0 0	0 0	44,556 0	412,880 0	0 0
(9) Margaret Juliana McElrath	(i) (ii)	232,458 0	0 0	0 0	14,400 0	44,791 0	291,649 0	0 0
(10) Ulrich W Mueller	(i) (ii)	222,869 0	30,000 0	0 0	0 0	47,322 0	300,191 0	0 0
(11) Howard Albert Nachtrieb	(i) (ii)	212,965 0	30,000 0	0 0	0 0	47,250 0	290,215 0	0 0
(12) Ross L Prentice	(i) (ii)	399,255 0	0 0	0 0	0 0	44,538 0	443,793 0	0 0
(13) Scott N Rusch	(i) (ii)	181,776 0	20,000 0	0 0	0 0	38,218 0	239,994 0	0 0
(14) Douglas J Shaeffer	(i) (ii)	289,538 0	30,000 0	0 0	0 0	44,807 0	364,345 0	0 0
(15) Myra H Tanita	(i) (ii)	398,212 0	75,000 0	0 0	6,000 0	39,780 0	518,992 0	0 0
(16) Barbara Trask	(i) (ii)	284,882 0	0 0	0 0	16,500 0	40,278 0	341,660 0	0 0
(17) Steven G Self	(i) (ii)	281,222 0	0 0	0 0	16,500 0	51,142 0	348,864 0	0 0
(18) F Marc Stewart	(i) (ii)	151,503 0	45,868 0	0 0	0 0	37,179 0	234,550 0	0 0
(19) Rainier F Storb	(i) (ii)	247,218 0	0 0	0 0	16,500 0	40,936 0	304,654 0	0 0
(20) James M Roberts	(i) (ii)	148,155 0	0 0	0 0	0 0	35,145 0	183,300 0	0 0
(21) Irwin D Bernstein	(i) (ii)	295,080 0	0 0	0 0	16,500 0	42,665 0	354,245 0	0 0
(22) Martin A Cheever	(i) (ii)	288,162 0	0 0	0 0	16,500 0	40,195 0	344,857 0	0 0
(23) Samir M Hanash	(i) (ii)	328,794 0	0 0	0 0	0 0	43,254 0	372,048 0	0 0
(24) Charles N Petty	(i) (ii)	262,694 0	0 0	0 0	0 0	36,995 0	299,689 0	0 0
(25) Henry F Warden	(i) (ii)	228,116 0	33,696 0	0 0	0 0	39,064 0	300,876 0	0 0

Schedule J (Form 990) 2010

Page 3

Part III

Supplemental Information

Complete this part to provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 4c, 5a, 5b, 6a, 6b, 7, and 8. Also complete this part for any additional information.

Identifier	Return Reference	Explanation
SchJ_P01_S00_L01a	Schedule J, Part I, Line 1a	First-class air travel is allowed consistent with federal reimbursement regulations and generally only when coach fare is not available. Airfare and normal travel expenses are paid for the President & Director's spouse for trips involving fundraising for the Center. Social club dues are paid for the Center's President & Director.

Schedule J (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule K
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information on Tax Exempt Bonds

Complete if the organization answered "Yes" to Form 990, Part IV, line 24a. Provide descriptions,
explanations, and any additional information in Schedule O (Form 990).
SchKMediumBullet

Attach to Form 990. SchKMediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number
23-7156071

Part I

Bond Issues

(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	(g) Defeased		(h) On Behalf of Issuer		(i) Pool financing
(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	Yes	No	Yes	No	Yes	No
A	Washington Health Care Facilities Authority	91-1108929		11-15-2007	5,200,000	See Part V.		X		X		X
B	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	15,381,009	Refund bonds issued 11/1/2002		X		X		X
C	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	8,842,608	Refund bonds issued 11/1/2002		X		X		X
D	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	32,093,411	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	18,735,275	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	39,972,686	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929		11-04-2010	30,000,000	Acquisition of a six-story office building		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	49,522,564	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	33,478,278	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	34,532,776	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	17,411,441	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	5,580,783	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	352,651	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	84,147,349	See Part V.		X		X		X

Part II

Proceeds

	A		B		C		D
	1 Amount of bonds retired. . . . .	425,274		454,841		261,490		949,053
2 Amount of bonds defeased . . . .	0		0		0		0
3 Total proceeds of issue . . . .	5,200,000		15,381,009		8,842,608		32,093,411
4 Gross proceeds in reserve funds . .	0		1,466,385		843,031		3,059,701
5 Capitalized interest from proceeds.	0		0		0		0
6 Proceeds in refunding escrow. . . . .	0		0		0		0
7 Issuance costs from proceeds . . .	35,948		169,304		97,333		353,262
8 Credit enhancement from proceeds.	0		0		0		0
9 Working capital expenditures from proceeds . .	32,182		69,174		39,769		144,336
10 Capital expenditures from proceeds . .	5,131,870		0		0		0
11 Other spent proceeds . .	0		0		0		0
12 Other unspent proceeds. . .	0		0		0		0
13 Year of substantial completion . . .	2007		2009		2009		2009
	Yes	No	Yes	No	Yes	No	Yes	No
14 Were the bonds issued as part of a current refunding issue?		X	X			X
15 Were the bonds issued as part of an advance refunding issue?		X		X		X		X
16 Has the final allocation of proceeds been made? . .	X		X		X		X
17 Does the organization maintain adequate books and records to support the final allocation of proceeds? .	X		X		X		X

Part III

Private Business Use

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Was the organization a partner in a partnership, or a member of an LLC, which owned property financed by tax-exempt bonds? . . .		X		X		X		X
2 Are there any lease arrangements that may result in private business use of bond-financed property? . . . . .		X		X		X		X

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50193E

Schedule K (Form 990) 2010

Page 2

Part III

Private Business Use (Continued)

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
3a Are there any management or service contracts that may result in private business use?		X		X		X		X
b Are there any research agreements that may result in private business use of bond-financed property? . .		X		X		X		X
c Does the organization routinely engage bond counsel or other outside counsel to review any management or service contracts or research agreements relating to the financed property? .	X		X		X		X
4 Enter the percentage of financed property used in a private business use by entities other than a section 501(c)(3) organization or a state or local government . . . . . . . . . . . . .	0 %		0 %		0.5 %
5 Enter the percentage of financed property used in a private business use as a result of unrelated trade or business activity carried on by your organization, another section 501(c)(3) organization, or a state or local government .	0 %		0 %		0 %
6 Total of lines 4 and 5 . . .. . . . . .	0 %		0 %		0 %		0 %
7 Has the organization adopted management practices and procedures to ensure the post-issuance compliance of its tax-exempt bond liabilities?	X		X		X		X

Part IV

Arbitrage

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Has a Form 8038-T, Arbitrage Rebate, Yield Reduction and Penalty in Lieu of Arbitrage Rebate, been filed with respect to the bond issue? . . .		X		X		X		X
2 Is the bond issue a variable rate issue?		X		X		X		X
3a Has the organization or the governmental issuer entered into a hedge with respect to the bond issue?		X		X		X		X
b Name of provider .	Barclays Bank PLC		Barclays Bank PLC		Barclays Bank PLC
c Term of hedge . .	17.5		17.5		17.5		17.5
d Was the hedge superintegrated? .		X		X		X		X
e Was a hedge terminated? .		X		X		X		X
4a Were gross proceeds invested in a GIC? .		X		X		X		X
b Name of provider .
c Term of GIC . .
d Was the regulatory safe harbor for establishing the fair market value of the GIC satisfied? .
5 Were any gross proceeds invested beyond an available temporary period? .		X		X		X		X
6 Did the bond issue qualify for an exception to rebate? . . .		X		X		X		X

Schedule K (Form 990) 2010

Page 3

Part V

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule K (see instructions).

Identifier	Return Reference	Explanation
SchK_P01_S00_L00	Schedule K, Part I	For the issue amount of $5,200,000 dated 11/15/2007, the description of purpose is to reimburse the Center for costs of acquiring real property and improvements and pay issuance costs.
SchK_P01_S00_L00c	Schedule K, Part I, Column c	No CUSIP available for $5,200,000 (DTD 11/15/2007) and $30,000,000 (DTD 11/04/2010).
SchK_P01_S00_L00f	Schedule K, Part I, Column f	For the CUSIP # 93978HBV6, bond issue amount of $84,147,349 dated 6/30/2011, the description of purpose is to repay a taxable bridge loan incurred by the Center to acquire land and the 1100 Eastlake Building in Seattle, Washington. To construct, remodel, renovate and equip health care facilities located at the 1100 Eastlake Building and at the Center's existing South Lake Union Campus in Seattle. To construct a connection between the 1100 Eastlake Building and the South Lake Union Campus.

Schedule K (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule K
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information on Tax Exempt Bonds

Complete if the organization answered "Yes" to Form 990, Part IV, line 24a. Provide descriptions,
explanations, and any additional information in Schedule O (Form 990).
SchKMediumBullet

Attach to Form 990. SchKMediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number
23-7156071

Part I

Bond Issues

(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	(g) Defeased		(h) On Behalf of Issuer		(i) Pool financing
(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	Yes	No	Yes	No	Yes	No
A	Washington Health Care Facilities Authority	91-1108929		11-15-2007	5,200,000	See Part V.		X		X		X
B	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	15,381,009	Refund bonds issued 11/1/2002		X		X		X
C	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	8,842,608	Refund bonds issued 11/1/2002		X		X		X
D	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	32,093,411	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	18,735,275	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	39,972,686	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929		11-04-2010	30,000,000	Acquisition of a six-story office building		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	49,522,564	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	33,478,278	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	34,532,776	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	17,411,441	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	5,580,783	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	352,651	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	84,147,349	See Part V.		X		X		X

Part II

Proceeds

	A		B		C		D
	1 Amount of bonds retired. . . . .	425,274		454,841		261,490		949,053
2 Amount of bonds defeased . . . .	0		0		0		0
3 Total proceeds of issue . . . .	5,200,000		15,381,009		8,842,608		32,093,411
4 Gross proceeds in reserve funds . .	0		1,466,385		843,031		3,059,701
5 Capitalized interest from proceeds.	0		0		0		0
6 Proceeds in refunding escrow. . . . .	0		0		0		0
7 Issuance costs from proceeds . . .	35,948		169,304		97,333		353,262
8 Credit enhancement from proceeds.	0		0		0		0
9 Working capital expenditures from proceeds . .	32,182		69,174		39,769		144,336
10 Capital expenditures from proceeds . .	5,131,870		0		0		0
11 Other spent proceeds . .	0		0		0		0
12 Other unspent proceeds. . .	0		0		0		0
13 Year of substantial completion . . .	2007		2009		2009		2009
	Yes	No	Yes	No	Yes	No	Yes	No
14 Were the bonds issued as part of a current refunding issue?		X	X			X
15 Were the bonds issued as part of an advance refunding issue?		X		X		X		X
16 Has the final allocation of proceeds been made? . .	X		X		X		X
17 Does the organization maintain adequate books and records to support the final allocation of proceeds? .	X		X		X		X

Part III

Private Business Use

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Was the organization a partner in a partnership, or a member of an LLC, which owned property financed by tax-exempt bonds? . . .		X		X		X		X
2 Are there any lease arrangements that may result in private business use of bond-financed property? . . . . .		X		X		X		X

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50193E

Schedule K (Form 990) 2010

Page 2

Part III

Private Business Use (Continued)

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
3a Are there any management or service contracts that may result in private business use?		X		X		X		X
b Are there any research agreements that may result in private business use of bond-financed property? . .		X		X		X		X
c Does the organization routinely engage bond counsel or other outside counsel to review any management or service contracts or research agreements relating to the financed property? .	X		X		X		X
4 Enter the percentage of financed property used in a private business use by entities other than a section 501(c)(3) organization or a state or local government . . . . . . . . . . . . .	0 %		0 %		0.5 %
5 Enter the percentage of financed property used in a private business use as a result of unrelated trade or business activity carried on by your organization, another section 501(c)(3) organization, or a state or local government .	0 %		0 %		0 %
6 Total of lines 4 and 5 . . .. . . . . .	0 %		0 %		0 %		0 %
7 Has the organization adopted management practices and procedures to ensure the post-issuance compliance of its tax-exempt bond liabilities?	X		X		X		X

Part IV

Arbitrage

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Has a Form 8038-T, Arbitrage Rebate, Yield Reduction and Penalty in Lieu of Arbitrage Rebate, been filed with respect to the bond issue? . . .		X		X		X		X
2 Is the bond issue a variable rate issue?		X		X		X		X
3a Has the organization or the governmental issuer entered into a hedge with respect to the bond issue?		X		X		X		X
b Name of provider .	Barclays Bank PLC		Barclays Bank PLC		Barclays Bank PLC
c Term of hedge . .	17.5		17.5		17.5		17.5
d Was the hedge superintegrated? .		X		X		X		X
e Was a hedge terminated? .		X		X		X		X
4a Were gross proceeds invested in a GIC? .		X		X		X		X
b Name of provider .
c Term of GIC . .
d Was the regulatory safe harbor for establishing the fair market value of the GIC satisfied? .
5 Were any gross proceeds invested beyond an available temporary period? .		X		X		X		X
6 Did the bond issue qualify for an exception to rebate? . . .		X		X		X		X

Schedule K (Form 990) 2010

Page 3

Part V

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule K (see instructions).

Identifier	Return Reference	Explanation
SchK_P01_S00_L00	Schedule K, Part I	For the issue amount of $5,200,000 dated 11/15/2007, the description of purpose is to reimburse the Center for costs of acquiring real property and improvements and pay issuance costs.
SchK_P01_S00_L00c	Schedule K, Part I, Column c	No CUSIP available for $5,200,000 (DTD 11/15/2007) and $30,000,000 (DTD 11/04/2010).
SchK_P01_S00_L00f	Schedule K, Part I, Column f	For the CUSIP # 93978HBV6, bond issue amount of $84,147,349 dated 6/30/2011, the description of purpose is to repay a taxable bridge loan incurred by the Center to acquire land and the 1100 Eastlake Building in Seattle, Washington. To construct, remodel, renovate and equip health care facilities located at the 1100 Eastlake Building and at the Center's existing South Lake Union Campus in Seattle. To construct a connection between the 1100 Eastlake Building and the South Lake Union Campus.

Schedule K (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule K
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information on Tax Exempt Bonds

Complete if the organization answered "Yes" to Form 990, Part IV, line 24a. Provide descriptions,
explanations, and any additional information in Schedule O (Form 990).
SchKMediumBullet

Attach to Form 990. SchKMediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number
23-7156071

Part I

Bond Issues

(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	(g) Defeased		(h) On Behalf of Issuer		(i) Pool financing
(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	Yes	No	Yes	No	Yes	No
A	Washington Health Care Facilities Authority	91-1108929		11-15-2007	5,200,000	See Part V.		X		X		X
B	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	15,381,009	Refund bonds issued 11/1/2002		X		X		X
C	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	8,842,608	Refund bonds issued 11/1/2002		X		X		X
D	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	32,093,411	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	18,735,275	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	39,972,686	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929		11-04-2010	30,000,000	Acquisition of a six-story office building		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	49,522,564	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	33,478,278	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	34,532,776	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	17,411,441	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	5,580,783	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	352,651	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	84,147,349	See Part V.		X		X		X

Part II

Proceeds

	A		B		C		D
	1 Amount of bonds retired. . . . .	425,274		454,841		261,490		949,053
2 Amount of bonds defeased . . . .	0		0		0		0
3 Total proceeds of issue . . . .	5,200,000		15,381,009		8,842,608		32,093,411
4 Gross proceeds in reserve funds . .	0		1,466,385		843,031		3,059,701
5 Capitalized interest from proceeds.	0		0		0		0
6 Proceeds in refunding escrow. . . . .	0		0		0		0
7 Issuance costs from proceeds . . .	35,948		169,304		97,333		353,262
8 Credit enhancement from proceeds.	0		0		0		0
9 Working capital expenditures from proceeds . .	32,182		69,174		39,769		144,336
10 Capital expenditures from proceeds . .	5,131,870		0		0		0
11 Other spent proceeds . .	0		0		0		0
12 Other unspent proceeds. . .	0		0		0		0
13 Year of substantial completion . . .	2007		2009		2009		2009
	Yes	No	Yes	No	Yes	No	Yes	No
14 Were the bonds issued as part of a current refunding issue?		X	X			X
15 Were the bonds issued as part of an advance refunding issue?		X		X		X		X
16 Has the final allocation of proceeds been made? . .	X		X		X		X
17 Does the organization maintain adequate books and records to support the final allocation of proceeds? .	X		X		X		X

Part III

Private Business Use

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Was the organization a partner in a partnership, or a member of an LLC, which owned property financed by tax-exempt bonds? . . .		X		X		X		X
2 Are there any lease arrangements that may result in private business use of bond-financed property? . . . . .		X		X		X		X

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50193E

Schedule K (Form 990) 2010

Page 2

Part III

Private Business Use (Continued)

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
3a Are there any management or service contracts that may result in private business use?		X		X		X		X
b Are there any research agreements that may result in private business use of bond-financed property? . .		X		X		X		X
c Does the organization routinely engage bond counsel or other outside counsel to review any management or service contracts or research agreements relating to the financed property? .	X		X		X		X
4 Enter the percentage of financed property used in a private business use by entities other than a section 501(c)(3) organization or a state or local government . . . . . . . . . . . . .	0 %		0 %		0.5 %
5 Enter the percentage of financed property used in a private business use as a result of unrelated trade or business activity carried on by your organization, another section 501(c)(3) organization, or a state or local government .	0 %		0 %		0 %
6 Total of lines 4 and 5 . . .. . . . . .	0 %		0 %		0 %		0 %
7 Has the organization adopted management practices and procedures to ensure the post-issuance compliance of its tax-exempt bond liabilities?	X		X		X		X

Part IV

Arbitrage

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Has a Form 8038-T, Arbitrage Rebate, Yield Reduction and Penalty in Lieu of Arbitrage Rebate, been filed with respect to the bond issue? . . .		X		X		X		X
2 Is the bond issue a variable rate issue?		X		X		X		X
3a Has the organization or the governmental issuer entered into a hedge with respect to the bond issue?		X		X		X		X
b Name of provider .	Barclays Bank PLC		Barclays Bank PLC		Barclays Bank PLC
c Term of hedge . .	17.5		17.5		17.5		17.5
d Was the hedge superintegrated? .		X		X		X		X
e Was a hedge terminated? .		X		X		X		X
4a Were gross proceeds invested in a GIC? .		X		X		X		X
b Name of provider .
c Term of GIC . .
d Was the regulatory safe harbor for establishing the fair market value of the GIC satisfied? .
5 Were any gross proceeds invested beyond an available temporary period? .		X		X		X		X
6 Did the bond issue qualify for an exception to rebate? . . .		X		X		X		X

Schedule K (Form 990) 2010

Page 3

Part V

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule K (see instructions).

Identifier	Return Reference	Explanation
SchK_P01_S00_L00	Schedule K, Part I	For the issue amount of $5,200,000 dated 11/15/2007, the description of purpose is to reimburse the Center for costs of acquiring real property and improvements and pay issuance costs.
SchK_P01_S00_L00c	Schedule K, Part I, Column c	No CUSIP available for $5,200,000 (DTD 11/15/2007) and $30,000,000 (DTD 11/04/2010).
SchK_P01_S00_L00f	Schedule K, Part I, Column f	For the CUSIP # 93978HBV6, bond issue amount of $84,147,349 dated 6/30/2011, the description of purpose is to repay a taxable bridge loan incurred by the Center to acquire land and the 1100 Eastlake Building in Seattle, Washington. To construct, remodel, renovate and equip health care facilities located at the 1100 Eastlake Building and at the Center's existing South Lake Union Campus in Seattle. To construct a connection between the 1100 Eastlake Building and the South Lake Union Campus.

Schedule K (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule K
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information on Tax Exempt Bonds

Complete if the organization answered "Yes" to Form 990, Part IV, line 24a. Provide descriptions,
explanations, and any additional information in Schedule O (Form 990).
SchKMediumBullet

Attach to Form 990. SchKMediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization
FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number
23-7156071

Part I

Bond Issues

(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	(g) Defeased		(h) On Behalf of Issuer		(i) Pool financing
(a) Issuer Name		(b) Issuer EIN	(c) CUSIP #	(d) Date Issued	(e) Issue Price	(f) Description of Purpose	Yes	No	Yes	No	Yes	No
A	Washington Health Care Facilities Authority	91-1108929		11-15-2007	5,200,000	See Part V.		X		X		X
B	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	15,381,009	Refund bonds issued 11/1/2002		X		X		X
C	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	8,842,608	Refund bonds issued 11/1/2002		X		X		X
D	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	32,093,411	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	18,735,275	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978E6G2	11-24-2009	39,972,686	Refund bonds issued 11/1/2002		X		X		X
	Washington Health Care Facilities Authority	91-1108929		11-04-2010	30,000,000	Acquisition of a six-story office building		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	49,522,564	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HCL7	06-30-2011	33,478,278	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	34,532,776	Refund bonds issued 11/15/2001		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	17,411,441	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBT1	06-30-2011	5,580,783	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	352,651	Refund bonds issued 11/24/2009		X		X		X
	Washington Health Care Facilities Authority	91-1108929	93978HBV6	06-30-2011	84,147,349	See Part V.		X		X		X

Part II

Proceeds

	A		B		C		D
	1 Amount of bonds retired. . . . .	425,274		454,841		261,490		949,053
2 Amount of bonds defeased . . . .	0		0		0		0
3 Total proceeds of issue . . . .	5,200,000		15,381,009		8,842,608		32,093,411
4 Gross proceeds in reserve funds . .	0		1,466,385		843,031		3,059,701
5 Capitalized interest from proceeds.	0		0		0		0
6 Proceeds in refunding escrow. . . . .	0		0		0		0
7 Issuance costs from proceeds . . .	35,948		169,304		97,333		353,262
8 Credit enhancement from proceeds.	0		0		0		0
9 Working capital expenditures from proceeds . .	32,182		69,174		39,769		144,336
10 Capital expenditures from proceeds . .	5,131,870		0		0		0
11 Other spent proceeds . .	0		0		0		0
12 Other unspent proceeds. . .	0		0		0		0
13 Year of substantial completion . . .	2007		2009		2009		2009
	Yes	No	Yes	No	Yes	No	Yes	No
14 Were the bonds issued as part of a current refunding issue?		X	X			X
15 Were the bonds issued as part of an advance refunding issue?		X		X		X		X
16 Has the final allocation of proceeds been made? . .	X		X		X		X
17 Does the organization maintain adequate books and records to support the final allocation of proceeds? .	X		X		X		X

Part III

Private Business Use

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Was the organization a partner in a partnership, or a member of an LLC, which owned property financed by tax-exempt bonds? . . .		X		X		X		X
2 Are there any lease arrangements that may result in private business use of bond-financed property? . . . . .		X		X		X		X

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50193E

Schedule K (Form 990) 2010

Page 2

Part III

Private Business Use (Continued)

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
3a Are there any management or service contracts that may result in private business use?		X		X		X		X
b Are there any research agreements that may result in private business use of bond-financed property? . .		X		X		X		X
c Does the organization routinely engage bond counsel or other outside counsel to review any management or service contracts or research agreements relating to the financed property? .	X		X		X		X
4 Enter the percentage of financed property used in a private business use by entities other than a section 501(c)(3) organization or a state or local government . . . . . . . . . . . . .	0 %		0 %		0.5 %
5 Enter the percentage of financed property used in a private business use as a result of unrelated trade or business activity carried on by your organization, another section 501(c)(3) organization, or a state or local government .	0 %		0 %		0 %
6 Total of lines 4 and 5 . . .. . . . . .	0 %		0 %		0 %		0 %
7 Has the organization adopted management practices and procedures to ensure the post-issuance compliance of its tax-exempt bond liabilities?	X		X		X		X

Part IV

Arbitrage

	A		B		C		D
	Yes	No	Yes	No	Yes	No	Yes	No
1 Has a Form 8038-T, Arbitrage Rebate, Yield Reduction and Penalty in Lieu of Arbitrage Rebate, been filed with respect to the bond issue? . . .		X		X		X		X
2 Is the bond issue a variable rate issue?		X		X		X		X
3a Has the organization or the governmental issuer entered into a hedge with respect to the bond issue?		X		X		X		X
b Name of provider .	Barclays Bank PLC		Barclays Bank PLC		Barclays Bank PLC
c Term of hedge . .	17.5		17.5		17.5		17.5
d Was the hedge superintegrated? .		X		X		X		X
e Was a hedge terminated? .		X		X		X		X
4a Were gross proceeds invested in a GIC? .		X		X		X		X
b Name of provider .
c Term of GIC . .
d Was the regulatory safe harbor for establishing the fair market value of the GIC satisfied? .
5 Were any gross proceeds invested beyond an available temporary period? .		X		X		X		X
6 Did the bond issue qualify for an exception to rebate? . . .		X		X		X		X

Schedule K (Form 990) 2010

Page 3

Part V

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule K (see instructions).

Identifier	Return Reference	Explanation
SchK_P01_S00_L00	Schedule K, Part I	For the issue amount of $5,200,000 dated 11/15/2007, the description of purpose is to reimburse the Center for costs of acquiring real property and improvements and pay issuance costs.
SchK_P01_S00_L00c	Schedule K, Part I, Column c	No CUSIP available for $5,200,000 (DTD 11/15/2007) and $30,000,000 (DTD 11/04/2010).
SchK_P01_S00_L00f	Schedule K, Part I, Column f	For the CUSIP # 93978HBV6, bond issue amount of $84,147,349 dated 6/30/2011, the description of purpose is to repay a taxable bridge loan incurred by the Center to acquire land and the 1100 Eastlake Building in Seattle, Washington. To construct, remodel, renovate and equip health care facilities located at the 1100 Eastlake Building and at the Center's existing South Lake Union Campus in Seattle. To construct a connection between the 1100 Eastlake Building and the South Lake Union Campus.

Schedule K (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

Schedule L
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Transactions with Interested Persons

Complete if the organization answered
"Yes" on Form 990, Part IV, lines 25a, 25b, 26, 27, 28a, 28b, or 28c,
or Form 990-EZ, Part V lines 38a or 40b.
MediumBullet

Attach to Form 990 or Form 990-EZ. MediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

Excess Benefit Transactions (section 501(c)(3) and section 501 (c)(4) organizations only).
Complete if the organization answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b.

1(a) Name of disqualified person	(b) Description of transaction	(c) Corrected?
1(a) Name of disqualified person	(b) Description of transaction	Yes	No

Enter the amount of tax imposed on the organization managers or disqualified persons during the year under section 4958. ......................... Bullet Image

Enter the amount of tax, if any, on line 2, above, reimbursed by the organization ....... Bullet Image

Part II

Loans to and/or From Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 26, or Form 990-EZ, Part V, line 38a.

(a) Name of interested person and purpose	(b) Loan to or from the organization?		(c)Original principal amount	(d)Balance due	(e) In default?		(f) Approved by board or committee?		(g)Written agreement?
(a) Name of interested person and purpose	To	From	(c)Original principal amount	(d)Balance due	Yes	No	Yes	No	Yes	No






Total ............... $

Part III

Grants or Assistance Benefitting Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 27.

(a) Name of interested person	(b)Relationship between interested person and the organization	(c)Amount of grant or type of assistance

For Privacy Act and Paperwork Reduction Act Notice, see the
Instructions for Form 990 or 990-EZ.

Cat. No. 50056A

Schedule L (Form 990 or 990-EZ) 2010

Page 2

Part IV

Business Transactions Involving Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of transaction	(d) Description of transaction	(e) Sharing of organization's revenues?
(a) Name of interested person		(c) Amount of transaction	(d) Description of transaction	Yes	No
(1) Jean McDougall	See Part V.	14,210	See Part V.		No
(2) Becton Dickenson	See Part V.	2,667,109	See Part V.		No
(3) Becton Dickenson	See Part V.	1,910,003	See Part V.		No
(4) Ikaria	See Part V.	512,264	See Part V.		No

Part V

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule L (see instructions).

Identifier	Return Reference	Explanation
SchL_P04_S00_L00	Schedule L, Part IV	1(a) Jean McDougall; (b) Daughter of Officer; (d) Compensation paid to interested person. 2(a) Becton Dickenson; (b) The spouse of B. Trask, who was an officer of the organization; (d) Research support received from interested person. 3(a) Becton Dickenson; (b) The spouse of B. Trask, who was an officer of the organization; (d) Medical supplies purchased from interested person. 4(a) Ikaria, (b) R. Nelson, organization trustee is a director of Ikaria; (d) Research support received from interested person.

Schedule L (Form 990 or 990-EZ) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

NonCash Contributions

Complete if the organization answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

Types of Property

	(a) Check if applicable	(b) Number of Contributions or items contributed	(c) Contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	56	6,408,528	Market Value
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( Equipment )	X	1	33,300	Market Value
26 Other ( Freight Delivery )	X	1	330	Market Value
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement ...

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1-28 that it

must hold for at least three years from the date of the initial contribution, and which is not required to be used

for exempt purposes for the entire holding period? ..................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell non-cash

contributions? ............................

32a

Yes

If "Yes," describe in Part II.

If the organization did not report revenues in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) 2010

Page 2

Part II

Supplemental Information. Complete this part to provide the information required by Part I, lines 30b,
32b, and 33. Also complete this part for any additional information.

Identifier	Return Reference	Explanation
SchM_P01_S00_L00	Schedule M, Part I	Column (b): Organization is reporting the number of contributions.
SchM_P01_S00_L32b	Schedule M, Part I, Line 32b	The Center employs KMS Financial Services to sell securities received as contributions.

Schedule M (Form 990) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Identifier	Return Reference	Explanation
F990_P06_S0B_L00	Form 990, Part VI, Section B	Line 11A - Under the Center's bylaws, the Finance Committee is responsible for reviewing and investigating financial transactions of FHCRC including responsibility of internal and external auditing and for making recommendations to the Board concerning these matters. FHCRC's Vice President of Finance & Chief Financial Officer and his staff work closely with the outside accounting firm FHCRC engages to review the Form 990. The draft of the Form 990 is also reviewed by the Corporate Treasurer, the Executive Vice President & Chief Operating Officer and the Vice President & General Counsel prior to providing it to the Finance Committee. The Finance Committee consults with the Chief Operating Officer, Chief Financial Officer, General Counsel and Corporate Treasurer and such other persons as the Finance Committee may designate to review the draft Form 990. Subsequent to its review, the Finance Committee reports to the Board regarding its oversight of the Form 990. The final draft is provided to the full Board prior to filing the return.
F990_P06_S0B_L11b	Form 990, Part VI, Section B, Line 11b	The final draft is provided to the full Board prior to filing the return.
F990_P06_S0B_L12c	Form 990, Part VI, Section B, Line 12c	The Executive Committee of the Board is responsible for monitoring conflicts of interest involving trustees or the president & Director of the Center. The President & Director of the Center is responsible for monitoring conflict of interest involving other officers, scientific staff and other key personnel designated by the President & Director. Under the FHCRC Conflict of Interest Policy and the related Guidelines, an annual conflict of interest disclosure document aimed at determining family and business relationships and transactions that constitute a conflict of interest under the policy, is distributed to and must be completed by all covered persons. Dislosures by trustees and the President & Director are reviewed by the Office of the General Counsel who reports any conflicts to the Executive Committee with recommendations on appropriate terms for a conflict management plan. Conflict management plans for trustees ot the President & Director are reviewed and approved by the Executive Committee and signed by the person with the conflict of interest and the Chair of the Board. Disclosure by members of the scientific staff, officers other than the President & Director and other key personnel designated by the President & Director are reviewed by the Office of the President & Dierctor, the Office of the General Counsel, and the Director of the division in which the person has his or her primary appointment or responsibilities. If a conflict is determined to exist under the policy a written conflict management plan is recommended by the Office of the General Counsel and approved and signed by the Office of the Director, the Office of the General Counsel and the Division Director as well as the person who has the conflict. Conflict management plans are designated to manage, reduce or eliminate conflicts to prevent bias, improper influence, or misuse of FHCRC or government resources. The conflict management plans for trustees usually require the affected trustee to recuse himself or herself from voting on any matters involving the affected transaction or relationship although he or she is allowed to provide factual information if requested by the Board of Executive COmmittee. All transactions requiring Board or committee approval must be approved by a majority of disinterested persons. Conflict management plans involving scientific staff, officer or other key personnel usually impose one of more of the following conditions or restrictions: i) publid disclosure of the interest; ii) monitoring of research by independent reviewers; iii) modification of the research plan; iv) disqualification from participation in all of or a portion of the research by the person with the conflict of interest; v) divesture of the interest; vi) severance of the relationship creating the conflict of interest.
F990_P06_S0B_L15	Form 990, Part VI, Section B, Line 15	Compemsation for the President & Director is determined and approved by the Board Compensation Committee. The compensation of other officers and key personnel at FHCRC is determined by the President & Director subject to ratification by the Compensation Committee. The Compensation Committee has developed, consistent with the organization's philosophy and principles, guidelines for determining compensation and benefits. The Compensation Committee also hires a qualified independent compensation specialist ("independent expert") to review, analyze and provide benchmarking data for the total compensation packages of all officers and key employees. Appropriate comparability data is obtained from the independent expert. No person with a conflict of interest may participate in determining or approving any executive compensation. Meetings of the Compensation Committee are documented in minutes which are approved at the next committee meeting. The above process was last undertaken in 2010 and updated in 2011 for the following positions: Sr VP & Dir, Clin Res Div; VP Shared Resources; Sr VP & Dir, Basic Sci; Sr VP & Co-Dir, VIDD; VP External Affairs & Comm; Sr VP & Deputy Dir, FHCRC; President & Director; VP & Chief Financial Officer; VP Industry Rel & Tech Transfer; VP Human Resources; Sr VP & Dir, PHS; VP Information Technology; Sr VP & Dir, Basic Sci; VP Operations & Facilities; VP General Counsel; Exec VP & COO; Sr VP & Dir, Human Biology; and VP & Dir, Development.
F990_P06_S0C_L19	Form 990, Part VI, Section C, Line 19	While federal tax laws do not mandate that the organization's governing documents, Conflict of Interest Policy and financial statements be made available for public inspection, the organization makes these documents available upon request.
F990_P11_S00_L05	Form 990, Part XI, Line 5	$10,316,186 = Change in net unrealized gains and losses in fair value of investment; $2,816,994 = Change in value of split-interest agreements; $2,494,930 = Change in net unrealized fair value of swap instruments. Total is $15,628,110.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2010

Additional Data

Software ID:	10000077
Software Version:	v1.00

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" to Form 990, Part IV, line 33, 34, 35, 36, or 37.
MediumBullet

Attach to Form 990. MediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

FRED HUTCHINSON CANCER RESEARCH CENTER

Employer identification number

23-7156071

Part I

Identification of Disregarded Entities (Complete if the organization answered "Yes" on Form 990, Part IV, line 33.)

(a) Name, address, and EIN of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

Part II

Identification of Related Tax-Exempt Organizations (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled organization
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No
(1) Seattle Vaccine Research Fund 1100 Fairview Ave North Seattle,WA98109 33-1111221	See Part VII.	WA	501(c)(3)	11a	N/A
(2) UPCID Ltd Upper Mulago Hill Road Kampala UG	See Part VII	UG	See Part VII	N/A	See Part VII

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2010

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership

Schedule R (Form 990) 2010

Page 3

Part V

Transactions With Related Organizations (Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35, 35A, or 36.)

Note. Complete line 1 if any entity is listed in Parts II, III or IV.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest (ii) annuities (iii) royalties (iv) rent from a controlled entity . . . . . . . . . . . . . . . . . . . . . . .

b Gift, grant, or capital contribution to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

c Gift, grant, or capital contribution from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

d Loans or loan guarantees to or for other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

e Loans or loan guarantees by other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

f Sale of assets to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

g Purchase of assets from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

h Exchange of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

i Lease of facilities, equipment, or other assets to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

j Lease of facilities, equipment, or other assets from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . .

k Performance of services or membership or fundraising solicitations for other organization(s) . . . . . . . . . . . . . . . . . . . . . .

l Performance of services or membership or fundraising solicitations by other organization(s) . . . . . . . . . . . . . . . . . . . . . .

m Sharing of facilities, equipment, mailing lists, or other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

n Sharing of paid employees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

o Reimbursement paid to other organization for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

p Reimbursement paid by other organization for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

q Other transfer of cash or property to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

r Other transfer of cash or property from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of other organization	(b) Transaction type(a-r)	(c) Amount involved	(d) Method of determining amount involved
(1) UPCID Ltd	b	359,000	Cash Transaction
(2) UPCID Ltd	n	54,000	Cash Transaction
(3)
(4)
(5)
(6)

Schedule R (Form 990) 2010

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership (Complete if the organization answered "Yes" on Form 990, Part IV, line 37.)

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Are all partners section 501(c)(3) organizations?		(e) Share of end-of-year assets	(f) Disproprtionate allocations?		(g) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(h) General or managing partner?
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(e) Share of end-of-year assets	Yes	No	(g) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Schedule R (Form 990) 2010

Page 5

Part VII

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule R (see instructions).

Identifier	Return Reference	Explanation
SchR_P02_S00_L00	Schedule R, Part II	Primary activity of Seattle Vaccine Research Fund: Anti-retrovital therapy for eligible participants. Address of UPCID: c/o Uganda Cancer Institute, POB 3935, Mulago Hospital, Upper Mulago Hill Road, Kampala, Uganda. Primary activity of UPCID, Ltd: Research and education regarding cancer and infectious diseases. Exempt Code section for UPCID, Ltd: Uganda Income Tax Act CAP 340, Section 2(bb). Direct controlling entity for UPCID, Ltd: Fred Hutchinson Cancer Research Center.

Additional Data

Software ID:	10000077
Software Version:	v1.00

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	345,330,959	388,454,000
9	Program service revenue (Part VIII, line 2g) .........	44,856,905	51,692,311
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	4,541,566	9,756,524
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	12,787,637	20,703,489
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)...................	407,517,067	470,606,324
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	62,506,551	80,189,368
14	Benefits paid to or for members (Part IX, column (A), line 4) ....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	205,262,594	214,220,175
16a	Professional fundraising fees (Part IX, column (A), line 11e)....	88,717	59,204
b	Total fundraising expenses (Part IX, column (D), line 25) 5,599,404
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24f)....	120,781,361	131,738,614
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	388,639,223	426,207,361
19	Revenue less expenses. Subtract line 18 from line 12......	18,877,844	44,398,963
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16)............	555,798,313	714,148,481
21	Total liabilities (Part X, line 26)............	362,793,049	461,116,144
22	Net assets or fund balances. Subtract line 21 from line 20 .....	193,005,264	253,032,337

Sign Here

	Signature of officer	Date

	Type or print name and title.

Paid Preparer's Use Only	Preparer's signature	Date	Check if self- employed	Preparer’s taxpayer identification number (see instructions)
	Firm’s name (or yours if self-employed), address, and ZIP + 4			EIN
				Phone no.


4a	(Code: ) (Expenses $ 97,970,042 including grants of $ 17,845,852 ) (Revenue $ 4,115,055 )
	Program Overview: The Center performs fundamental research in clinical, basic and population science disciplines; exhibits a special competence as a designated research center; serves as a focal point for testing and evaluating outputs of research and development efforts; and couples the outputs of cancer research efforts with medical practice. The Center performs these functions through its five scientific research divisions: Public Health Sciences, Clinical Research, Basic Sciences, Human Biology and Vaccine and Infectious Disease. Public Health Sciences ("PHS") The Division of Public Health Sciences' mission is to identify strategies that will ultimately reduce the incidence of and mortality from cancer and other diseases. PHS faculty focus on determining causes of cancer, helping to identify and assess effective screening and treatment methods, developing prevention strategies that reduce the risk of cancer, and developing research strategies to assist people to change behaviors toward healthier lifestyles. This prevention-oriented research also extends to other diseases, including HIV/AIDS, cardiovascular disease, diabetes, and fractures. The Division of Public Health Sciences is home to the nation's oldest and largest program devoted to cancer-prevention research-an important endeavor, considering that many cancers may be avoidable by changes in lifestyle. The PHS Division is organized into six administrative programs. Each of these programs has a faculty with a wide range of interests and an interactive and interdisciplinary research orientation. These programs are as follows: Biostatistics and Biomathematics - The Biostatistics & Biomathematics Program provides statistical collaboration and coordination for research programs within and outside the center, develops and evaluates new quantitative methods for the efficient design and analysis of a broad range of biomedical studies and constructs biomathematical models of carcinogenesis and other biological processes. Cancer Biology - The Cancer Biology Program applies molecular biology, genetics, pathology, epidemiology, and biostatistics to studies of human populations, focusing on the root causes of cancer. Cancer Prevention - The Cancer Prevention Program uses interdisciplinary approaches to evaluate the causes, detection and control of cancer in laboratory, clinic and community-based studies. Computational Biology - Scientists within the Computational Biology Program use and develop computational methods and tools to address biological questions. The Program encompasses a wide range of bioinformatic and computational approaches. Epidemiology - The Epidemiology Program seeks to determine the causes of cancers through studies in human populations of personal exposures, behavioral characteristics, and genes that may influence a person's chances of developing one or more cancers. Molecular Diagnostics - The Molecular Diagnostics Program works to discover accurate methods for determining an individual's cancer risk; detecting cancer at its earliest, most curable stage; classifying the type and extent of cancer, once diagnosed; and monitoring response to therapy and disease progression.

4b	(Code: ) (Expenses $ 86,645,261 including grants of $ 8,886,306 ) (Revenue $ 13,263,449 )
	Clinical Research Division: From laboratory bench to bedside, the Clinical Research Division works to develop and analyze new treatments for cancers and other diseases. Researchers seek new or improved ways to cure cancer. Foremost among their contributions has been the development of bone marrow transplantation, a technique that is now saving tens of thousands of lives worldwide annually. In 1990, Dr. E. Donnall Thomas, director emeritus of the Clinical Research Division, received the Nobel Prize in physiology or medicine for his pioneering work developing this technique. Through clinical research, Center scientists continue to refine the techniques of transplantation and extend its use. Once exclusively used for treatment of leukemia, lymphomas and similar diseases, bone marrow transplantation is now being successfully applied to a growing number of diseases, including breast, ovarian and kidney cancer, sickle cell disease and autoimmune disorders such as multiple sclerosis and scleroderma. Other avenues of research being conducted in the Clinical Research Division include immunotherapy, antibody therapy and cancer vaccines. Approximately 450 patients from all over the world receive transplants at the Seattle Cancer Care Alliance coordinated by researchers from the Center's Bone Marrow Transplant Program. The Seattle Cancer Care Alliance, established in 1998, unites the adult and pediatric cancer-care services of the Hutchinson Center, UW Medicine and Seattle Children's. A major focus of SCCA is to speed the transfer of new diagnostic and treatment techniques from the research setting to the patient bedside while providing premier, patient-focused cancer care. Thousands of other cancer patients will be able to receive similar treatment in their local hospitals as a result of the knowledge shared by Clinical Research Division scientists with physicians around the world. Because of the Center's training efforts, many hospitals throughout the United States now perform bone marrow transplants. Scientists in the Center's Clinical Research Division have recorded several "firsts" in cancer research and treatment: * Showing that patients with acute leukemia who have failed chemotherapy can be cured with bone marrow transplantation. * Showing that bone marrow transplantation is the best form of initial therapy for patients with acute myelogenous leukemia, a disease that affects approximately 15,000 Americans each year. * Showing that bone marrow transplantation can cure chronic myelogenous leukemia, a disease that is otherwise incurable and affects approximately 3,000 Americans each year. * Developing the first FDA-approved antibody-targeted chemotherapy, making chemotherapy less toxic and more effective. * Pioneering the first antibody-targeted therapy against a marker specific to non-Hodgkins lymphoma, an approach now used to treat thousands of people each year. * Developing a "tumor paint" that will help surgeons see where a tumor begins and ends more precisely by illuminating the cancerous cells. The tumor paint, derived from scorpion venom, was developed in collaboration with researchers at Seattle Children's Hospital Research Institute. The high quality of the research conducted in the Center's Clinical Research Division is matched only by the quality of care provided to patients receiving treatment.

4c	(Code: ) (Expenses $ 120,336,383 including grants of $ 43,937,224 ) (Revenue $ 5,054,513 )
	Vaccine and Infectious Disease Division ("VIDD") The Vaccine and Infectious Disease Division (VIDD) scientists integrate clinical care, computational methods and basic science research to reduce the global burden of infectious disease. VIDD has over 50 faculty members who specialize in a range of disciplines that synergize and complement one another. Administratively, VIDD also encompasses major networks and service programs as well as clinical consulting services in infectious diseases. The multidisciplinary nature of VIDD's faculty and services provide a robust and cohesive scientific community. VIDD research programs integrate the latest in computational, laboratory and clinical research methods to advance the understanding of microbial pathogenesis and infectious disease processes. VIDD researchers partner with scientists at laboratory, clinical and field sites in Africa, Asia and Europe. The Division has specific initiatives in Uganda, China and the Republic of South Africa to advance the understanding of infection-related cancers and infectious diseases that affect high-risk populations in these regions. VIDD scientists around the world including clinicians, clinical trials specialists, statisticians, computational biologists and basic scientists take pride in their collaborative efforts to predict, detect, treat and prevent infectious diseases in humans.

	(Code: ) (Expenses $ 97,769,315 including grants of $ 9,519,986 ) (Revenue $ 29,259,294 )
	(Expenses $97,769,315 including grants of $9,519,986) (Revenue $29,259,294)

4d	Other program services. (Describe in Schedule O.)
	(Expenses $ 97,769,315 including grants of $ 9,519,986 ) (Revenue $ 29,259,294 )
4e	Total program service expenses$ 402,721,001

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)............	7,828,589	0	1,137,431

1	Briefly describe the organization’s mission or most significant activities: The mission of the Fred Hutchinson Cancer Research Center is the elimination of cancer and related diseases as causes of human suffering and death. The Center conducts research of the highest standards to improve prevention and treatment of cancer and related diseases.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ....	3	20
4	Number of independent voting members of the governing body (Part VI, line 1b) ....	4	19
5	Total number of individuals employed in calendar year 2010 (Part V, line 2a) ...	5	3,117
6	Total number of volunteers (estimate if necessary) ....	6	400
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ..	7a	-85,743
b	Net unrelated business taxable income from Form 990-T, line 34 ..	7b	-85,743

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512, 513, or 514
1a	Federated campaigns..1a		658,821
b	Membership dues....1b		0
c	Fundraising events....1c		7,416,286
d	Related organizations...1d		0
e	Government grants (contributions)1e		319,314,618

f	All other contributions, gifts, grants, and similar amounts not included above1f		61,064,275
g	Noncash contributions included in lines 1a-1f:$ 6,442,158
h	Total. Add lines 1a-1f.......			388,454,000
			Business Code
2a	Research Activities		900,099	12,808,946	12,808,946	0	0
b	Interaffiliate Agreements & Services		900,099	29,259,294	29,259,294	0	0
c	Patient Services at SCCA		900,099	9,624,071	9,624,071	0	0
d
e
f	All other program service revenue .			0	0	0	0
g	Total. Add lines 2a–2f........			51,692,311
3	Investment income (including dividends, interest
	and other similar amounts).....			3,266,921	0	-85,743	3,352,664
4	Income from investment of tax-exempt bond proceeds..			202,743	0	0	202,743
5	Royalties............			18,424,245	0	0	18,424,245
		(i) Real	(ii) Personal
6a	Gross Rents	2,738,491	0
b	Less: rental expenses	0	0
c	Rental income or (loss)	2,738,491	0
d	Net rental income or (loss).......			2,738,491	0	0	2,738,491
		(i) Securities	(ii) Other
7a	Gross amount from sales of assets other than inventory	101,879,000	48,250
b	Less: cost or other basis and sales expenses	95,640,390	0
c	Gain or (loss)	6,238,610	48,250
d	Net gain or (loss)..........			6,286,860	0	0	6,286,860
8a	Gross income from fundraising events (not including $ 7,416,286 of contributions reported on line 1c). See Part IV, line 18 ...
	a		520,665
b	Less: direct expenses ...b		979,912
c	Net income or (loss) from fundraising events..			-459,247		0	-459,247
9a	Gross income from gaming activities. See Part IV, line 19 ...
	a		0
b	Less: direct expenses ...b		0
c	Net income or (loss) from gaming activities...			0	0	0	0
10a	Gross sales of inventory, less returns and allowances .
	a		0
b	Less: cost of goods sold ..b		0
c	Net income or (loss) from sales of inventory..			0	0	0	0
Miscellaneous Revenue			Business Code
11a
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			0
12	Total revenue. See Instructions....			470,606,324	51,692,311	-85,743	30,545,756


				(A) Beginning of year		(B) End of year
1	Cashnon-interest-bearing ..........			15,274	1	9,037
2	Savings and temporary cash investments .......			35,926,246	2	61,510,742
3	Pledges and grants receivable, net .........			32,217,752	3	34,026,493
4	Accounts receivable, net .........			18,479,708	4	18,046,009
5	Receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of
	Schedule L ..........				5
6	Receivables from other disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B). Complete Part II of
	Schedule L ..........				6
7	Notes and loans receivable, net .............			695,757	7	621,757
8	Inventories for sale or use ..............				8
9	Prepaid expenses and deferred charges ............			1,164,713	9	1,446,837
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	626,737,871
b	Less: accumulated depreciation. .....	10b	301,381,978	265,178,985	10c	325,355,893
11	Investments—publicly traded securities ..........			58,983,024	11	125,674,643
12	Investments—other securities. See Part IV, line 11 ......			48,090,908	12	40,827,536
13	Investments—program-related. See Part IV, line 11 ..			59,784,031	13	71,213,967
14	Intangible assets .........			0	14
15	Other assets. See Part IV, line 11 ...........			35,261,915	15	35,415,567
16	Total assets. Add lines 1 through 15 (must equal line 34)...			555,798,313	16	714,148,481
17	Accounts payable and accrued expenses .			38,025,954	17	35,760,069
18	Grants payable ..........			0	18	0
19	Deferred revenue ..........			29,178,432	19	26,711,012
20	Tax-exempt bond liabilities ..........			266,607,522	20	372,159,052
21	Escrow or custodial account liability. Complete Part IV of Schedule D..			0	21	0
22	Payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........			0	22	0
23	Secured mortgages and notes payable to unrelated third parties ..			0	23	0
24	Unsecured notes and loans payable to unrelated third parties ....			0	24	0
25	Other liabilities. Complete Part X of Schedule D.....			28,981,141	25	26,486,011
26	Total liabilities. Add lines 17 through 25.....			362,793,049	26	461,116,144
	Organizations that follow SFAS 117, check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets .....			114,011,264	27	162,996,337
28	Temporarily restricted net assets .....			32,312,000	28	38,223,000
29	Permanently restricted net assets .....			46,682,000	29	51,813,000
	Organizations that do not follow SFAS 117, check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds .....				30
31	Paid-in or capital surplus, or land, building or equipment fund .....				31
32	Retained earnings, endowment, accumulated income, or other funds				32
33	Total net assets or fund balances .....			193,005,264	33	253,032,337
34	Total liabilities and net assets/fund balances .....			555,798,313	34	714,148,481

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926 (see instructions for Form 926).................	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If " Yes," the organization may be required to file Form 3520 and/or Form 3520-A. (see instructions for Forms 3520 and 3520-A)..........	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with respect to Certain Foreign Corporations. (see instructions for Form 5471)..............................	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If "Yes," the organization may be required to file Form 8621, Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see instructions for Form 8621)	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with respect to Certain Foreign Partnerships. (see instructions for Form 8865)....................................	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to file Form 5713, International Boycott Report (see instructions for Form 5713)................................................	Yes	No